

CURRICULUM VITAE**Susan F. Leitman, M.D.**

Home Address: 2 Candlelight Court
Potomac, Maryland 20854

Office Address: Medical Research Scholars Program
Office of Clinical Research Training and Medical Education
National Institutes of Health
Building 10, Room IN-248
9000 Rockville Pike
Bethesda, Maryland 20892

Place of Birth: Montreal, Canada

Current Positions:

2014 - present Director, Medical Research Scholars Program,
Office of Clinical Research Training and Medical Education,
National Institutes of Health, Bethesda, MD

2014 - present Special Volunteer, Department of Transfusion Medicine,
Clinical Center, National Institutes of Health, Bethesda, MD

Education:

1977 M.D., Brown University, Warren Alpert Medical School
1974 B.A., Brown University

Postdoctoral Training:

1983 - 85 Senior Staff Fellow, Clinical Center Blood Bank
National Institutes of Health, Bethesda, Maryland

1980 - 83 Fellow in Hematology-Oncology, Hospital of the University of
Pennsylvania, Philadelphia, PA

1978 - 80 Resident in Medicine, Hospital of the University of Pennsylvania,
Philadelphia, PA

1977 - 78 Intern in Medicine, Hospital of the University of Pennsylvania,
Philadelphia, PA

Other Academic and Previous Positions:

1985 - 2013 Chief, Blood Services Section, Department of Transfusion Medicine,
National Institutes of Health, Bethesda, MD

1992 - 2011 Deputy Chief, Department of Transfusion Medicine
National Institutes of Health, Bethesda, MD

2003 Acting Chief, Department of Transfusion Medicine, July - Dec, 2003
National Institutes of Health, Bethesda, Maryland

1983 - present Faculty Instructor, Specialty in Blood Banking Training Program
Department of Transfusion Medicine, NIH, Bethesda, MD

1988 - 98	Clinical Associate Professor, Dept of Medicine (Hematology), Georgetown University Medical Center, Washington, DC
1983 - 93	Lecturer, Foundation for Advanced Education in the Sciences, NIH Course Title: Immunohematology

Current and Past Boards, Committees and Other Positions:

2016 - present	President and Chairman, Board of Directors, Foundation for Advanced Education in the Sciences (FAES), NIH
2014 - present	Member, Blood Products Advisory Committee Center for Biologics Evaluation and Research, FDA
2009 - present	Member and Vice President, Board of Directors, FAES, NIH
2005 - present	Member, Selection of Abstracts Program Unit, American Association of Blood Banks (AABB)
2004 - present	Board of Advisors, Medical Research Scholars Program and Clinical Research Training Program, NIH
2003 - 2013	Member, Standards Committee, National Marrow Donor Program
2004 - 2009	Co-Chair, Working Committee on Donor Health and Safety, Center for International Blood and Marrow Transplant Registry (CIBMTR)
2004	Steering Committee, Conference on Safeguarding Adult and Pediatric Stem Cell Donors: Basic Science, Clinical and Ethical Issues. Sponsored by NHLBI, AABB, ASBMT, NMDP, CIBMTR, WMDA, ISCT, FDA; September 2004, Arlington, VA.
2003 - 2005	Vice-Chair, Board of Directors, National Marrow Donor Program
2002 - 2006	Member, Transmissible Spongiform Encephalopathies Committee, Center for Biologics Evaluation and Research, FDA
1996 -2002	Ad Hoc Member, Biologic Response Modifier Advisory Committee, Center for Biologics Evaluation and Research, FDA
1998 - 1999	Council President, National Marrow Donor Program
1996 - 2006	Member, Board of Directors, National Marrow Donor Program
1996 - 1998	Vice President for Donor Centers, National Marrow Donor Program
1995 - 2005	Member, NIH Clinical Center Promotion and Tenure Committee
1995 - 1998	Member, NIH Clinical Center Technology Development Committee
1994 - 1996	Member, Scientific Program Committee, AABB
1993 - 1997	Member, Blood Products Advisory Committee Center for Biologics Evaluation and Research, FDA
1992 - 1998	Member (Chair 1996-1998), Donor and Patient Safety Monitoring Committee, National Marrow Donor Program
1991 - 1993	Member, Transfusion Practice Quality Assurance Committee, AABB
1989 - 1994	Co-Chair, Scientific Program Committee Mid-Atlantic Association of Blood Banks
1988 - 1994	Member, Clinical Applications Committee American Society for Apheresis
1987 - 1994	Member (Chair 1990-1994), Hemapheresis Committee, AABB

Editorial Boards:

1995 - present	NIH Catalyst
1990 - 1998	Journal of Clinical Apheresis
1991 - 1996	Transfusion

Certification:

1980 Diplomat, American Board of Internal Medicine
1983 Diplomat, American Board of Internal Medicine
Subspecialty of Medical Oncology
1984 Diplomat, American Board of Pathology
Subspecialty of Blood Banking

Medical License: Commonwealth of Pennsylvania

Selected Awards and Honors:

1974 Phi Beta Kappa
1974 Sigma Xi
1982 PHS National Research Service Award
1986 NIH Special Achievement Award
1991 Arthur S. Flemming Award, Scientific Division
1997 Charles E. Walter Memorial Award,
Mid-Atlantic Association of Blood Banks
1999 NIH Distinguished Clinical Teacher Award
2004 NIH Clinical Center Director's Award
2004 Iron Disorders Institute "Making a Difference" Award
2009 Honorary Lectureship, Hospital Albert Einstein Annual Symposium on
Hematology and Hemotherapy, Sao Paulo, Brazil
2010 Eugene M. Berkman Honorary Lectureship in Transfusion Medicine,
Tufts University Medical Center, Boston, MA
2012 Liam O'Connell Honorary Lectureship & Award, Hematology
Association of Ireland, Cork, Ireland
2014 Richard J. Davey Lectureship Award, DTM Annual
Immunohematology Symposium, NIH Clinical Center
2017 Francis S. Morrison Memorial Lectureship, American Society for
Apheresis, Fort Lauderdale, FL

Patents:

2001 Bolan CD, Cullis H, Leitman SF. Apheresis Methods And Devices:
Coupled calcium/citrate delivery system. DHHS Reference No. E-
001-2001/1-US-02. Filed Nov. 3, 2000.

Membership in Professional and Scientific Societies:

American Society of Hematology
American Association of Blood Banks
American Society for Apheresis
National Marrow Donor Program

ORIGINAL PAPERS

1. Anaclerio A, **Leitman S**, Galliette R, Heppner G, Calabresi P: Stimulatory effects of 5-iodo-2'-deoxyuridine on number and function of splenic T-cells and of macrophages in C3HeB/FeJ mice. *Cancer Research* 36:73-76, 1976.
2. Bennett JS, Hoxie JA, **Leitman SF**, Vilaire G, Cines, DB: Inhibition of fibrinogen binding to stimulated human platelets by a monoclonal antibody. *Proc Natl Acad Sci, USA* 80:2417-2421, 1983.
3. **Leitman SF**, and Holland PV: Irradiation of blood products: Indications and guidelines. *Transfusion* 25:293-300, 1985.
4. Rosenberg SA, Lotze MT, Muul LM, **Leitman SF**, Chang AE, Ettinghausen SE, et al: Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. *N Engl J Med* 313:1485-1492, 1985.
5. Rosenberg SA, Lotze MT, Muul LM, **Leitman SF**, Chang AE, Vetto JT, et al: A new approach to the therapy of cancer based on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2. *Surgery* 100:262-270, 1986.
6. **Leitman SF**, Boltansky H, Alter HJ, Pearson FC, Kaliner MA: Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. *N Engl J Med* 15:1192-1196, 1986.
7. Stevenson HC, Stevenson GW, **Leitman SF**, Carter CS, Alvord G, Klein HG: The isolation of human mononuclear leukocyte subsets by cytophoresis for laboratory research. *Plasma Ther Transfus Technol* 7:365-371, 1986.
8. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, **Leitman SF**, et al: Clinical experience with treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. *N Engl J Med* 316:889-897, 1987.
9. Carter CS, **Leitman SF**, Cullis H, Muul LM, Rosenberg SA, Klein HG: Use of a continuous-flow cell separator in density gradient isolation of lymphocytes. *Transfusion* 27:362-365, 1987.
10. Muul LM, Carter CS, Cullis H, **Leitman SF**, Klein HG, Rosenberg SA, et al: Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy. *J Immunolog Methods* 101:171-181, 1987.
11. Adde MA, **Leitman SF**: Nursing considerations in the clinical management of patients undergoing selective removal of LDL using secondary membrane filtration: *J Clin Apheresis* 4:82-84, 1988.
12. Carter CS, **Leitman SF**, Cullis H, Muul LM, Rosenberg SA, Klein HG: Technical aspects of lymphokine-activated killer cell production. *J Clin Apheresis* 4:113-117, 1988.

13. Aebersold P, Carter CS, Hyatt C, Johnson S, **Leitman SF**, Rosenberg SA: A simplified procedure for generation of human lymphokine-activated killer cells for use in clinical trials. *J Immunolog Methods* 112:1-7, 1988.
14. Read EJ, Kodis C, Carter CS, **Leitman SF**: In vivo survival of platelets following storage in the irradiated state: A pair-controlled study. *Transfusion* 28:446-450, 1988.
15. Klein HG, **Leitman, SF**: Adoptive immunotherapy in the treatment of malignant disease. *Transfusion* 29:170-178, 1989.
16. DePalma L, **Leitman SF**, Carter CS, Gallin JI: Granulocyte transfusion therapy in a child with chronic granulomatous disease and multiple red cell alloantibodies. *Transfusion* 29:421-423, 1989.
17. **Leitman SF**, Smith J, Gregg RE: Homozygous familial hypercholesterolemia: selective removal of low density lipoproteins by secondary membrane filtration. *Transfusion* 29:341-346, 1989.
18. **Leitman SF**, Klein HG, Melpolder JJ, Read EJ, Esteban JI, Leonard EM, Harvath L, Shih JWK, Nealon R, Foy J, Darr F, Alter HJ: Clinical implications of positive tests for antibodies to human immunodeficiency virus type 1 in asymptomatic blood donors. *N Engl J Med* 321:917-924, 1989.
19. **Leitman SF**: Use of blood cell irradiation in the prevention of posttransfusion graft-versus-host disease. *Transfusion Science* 10:219-232, 1989.
20. Loiacono B, Carter GR, Carter CS, **Leitman SF**, Klein HG: Efficacy of various methods of confidential unit exclusion in identifying potentially infectious blood donations. *Transfusion* 29:823-826, 1989.
21. DePalma L, Palmer R, **Leitman SF**, Dolan WD, Klein HG: Utilization patterns of frozen autologous red blood cells; experience in a referral center and a community hospital. *Arch Pathol Lab Med* 114:516-518, 1990.
22. Lane HC, Zunich KM, Wilson W, Cefali F, Easter M, Kovacs JA, Masur H, **Leitman SF**, Klein HG, Steis RG, Longo DL, Fauci AS: Syngeneic bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes combined with zidovudine in human immunodeficiency virus (HIV) infection. *Ann Intern Med* 113:512-519, 1990.
23. DePalma L, Criss VR, Sullivan MT, **Leitman SF**, Williams AE, Luban NLC: Detection of cytomegalovirus antibody in platelet concentrates by fluorescent immunoassay and latex agglutination. *Transfusion* 31:245-248, 1991.
24. Shih JWK, Kung K, Pottathil R, **Leitman SF**, Klein HG, Melpolder JJ, Alter HJ: Quantitative analysis of an HIV positive blood donor cohort. In: Andrieu, JM, ed. *Viral quantitation in HIV infection*. John Libbey Eurotext, Paris. P. 171-176, 1991.
25. Shirai A, Cosentino M, **Leitman SF**, Klinman DM: Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. *J Clin Invest* 89:561-566, 1992.

26. Miller FW, **Leitman SF**, Cronin ME, Hicks JE, Leff RL, Wesley R, Fraser DD, Dalakas M, Plotz PH. Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis. *N Engl J Med* 326:1380-1384, 1992.
27. Davey RJ, McCoy NC, Yu M, Sullivan JA, Spiegel DM, **Leitman SF**: The effect of prestorage irradiation on posttransfusion red cell survival. *Transfusion* 32:525-528, 1992.
28. Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM, Illingworth DR, Jones PH, **Leitman SF**, Stein EA, Stern TN, Zavoral JH, Zweiner J: Multicenter controlled study of the treatment of refractory familial hypercholesterolemia by LDL-apheresis using the Liposorber LA-15 System. *Am J Cardiol* 70:1010-1016, 1992.
29. Suda BA, **Leitman SF**, Davey RJ: Characteristics of red cells irradiated and subsequently frozen for long term storage. *Transfusion* 33:389-392, 1993.
30. **Leitman SF**. Dose, dosimetry, and the quality control of irradiated blood components. (Editorial). *Transfusion* 33:447-449, 1993.
31. Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang FE, Aebersold P, **Leitman SF**, Linehan WM, Steinberg SM. Prospective randomized trial of high dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. *J Natl Cancer Inst* 85:622-632, 1993.
32. Pockaj BA, Sherry R, Yanelli JR, Carter CS, **Leitman SF**, Carrasquillo JR, Rosenberg SA, Yang JC. Localization of ¹¹¹Indium-labelled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. *Cancer* 73:1731-1737, 1994.
33. Stehling L, Luban NLC, Anderson KC, Sayers MH, Long A, Attar S, **Leitman SF**, Gould SA, Kruskall MS, Goodnough LT, Hines DM. Guidelines for blood utilization review. *Transfusion* 34:438-448, 1994.
34. Cole DJ, Taubenberger JK, Pockaj BA, Yanelli JR, Carter CS, Carrasquillo J, **Leitman SF**, Steinberg SM, Rosenberg SA, Yang JC. Histopathologic analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor infiltrating lymphocytes. *Cancer Immunol Immunother* 38:299-303, 1994.
35. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Fox MC, **Leitman SF**, Gottesman M, Pastan I, Gress R. Clinical Protocol: Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. *Human Gene Therapy* 5:891-911, 1994.
36. Lekstrom JA, Holland SM, DeCarlo ES, Miller J, **Leitman SF**, Chang R, Baker AR, Gallin JI. Treatment with intralesional granulocyte instillations and interferon-gamma for a patient with chronic granulomatous disease and multiple hepatic abscesses. *J Clin Infect Dis* 19:770-773, 1994.
37. Cosentino M, **Leitman SF**, Klinman DM. HIV-specific B cells localize to the bone marrow of gp160-immunized mice and humans. *Vaccine Research* 3:195-199, 1994.

38. Chen CC, Kerr GS, Carter CS, Read EJ, Carrasquillo JA, **Leitman SF**, Hoffman GS. Lack of sensitivity of indium-111 mixed leukocyte scans for active disease in Takayasu's Arteritis. *Am J Rheumatol* 22:478-481, 1995.
39. Dunbar CE, Cottler-Fox M, O'Shaughnessy JA, Doren S, Carter CS, Berenson R, Brown S, Greenblatt J, Stewart F M, **Leitman SF**, Wilson WH, Cowan K, Young NS, Nienhuis AW. Retrovirally-marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. *Blood* 85:3048-3057, 1995.
40. Lee JH, **Leitman SF**, Klein HG. A controlled comparison of the efficacy of hetastarch and pentastarch in granulocyte collection by centrifugal leukapheresis. *Blood* 86:4662-4666, 1995.
41. Lee JH, Cullis H, **Leitman SF**, Klein HG. The efficacy of pentastarch in granulocyte collection by centrifugal leukapheresis. *Journal of Clinical Apheresis* 10:198-202, 1995.
42. Hagiwara E, Sacks T, **Leitman SF**, Klinman DM. Effect of HIV infection on the frequency of cytokine-secreting cells in human peripheral blood. *AIDS Research and Human Retroviruses* 12:127-131, 1996.
43. Sekhsaria S, Fleisher TA, Vowells S, Brown M, Miller J, Gordon I, Blaese MR, Dunbar CE, **Leitman SF**, Malech HL. Granulocyte colony-stimulating factor recruitment of CD34+ progenitors to peripheral blood: impaired mobilization in chronic granulomatous disease and adenosine deaminase-deficient SCID patients. *Blood* 88:1104-1112, 1996.
44. **Leitman SF**, Read EJ. Hematopoietic Progenitor Cells. In: Klein HG (editor). *Transfusion Medicine*. *Sem Hematol* 33:341-358, 1996.
45. Stroncek DF, Leonard K, Eiber G, Malech HL, Gallin JI, **Leitman SF**. Alloimmunization after granulocyte transfusions. *Transfusion* 36:1009-1015, 1996.
46. Malech HL, Maples PB, Whiting-Theobald N, Linton G F, Sekhsaria S, Vowells SJ, Li F, Miller JA, DeCarlo E, Holland SM, **Leitman SF**, Carter CS, Read EJ, Fleisher TA, Schneiderman RD, Van Epps DE, Maack CA, Rokovich JA, Cohen LK, Gallin JI. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. *Proc Natl Acad Sci USA* 94, 12133-12138, 1997.
47. Emmons RVB, Doren S, Zujewski J, Cottler-Fox M, Carter CS, O'Shaughnessy JA, **Leitman SF**, Greenblatt JJ, Cowan K, Dunbar CE. Retroviral gene transduction of adult peripheral blood or marrow-derived CD34+ cells for six hours without growth factors or on autologous stroma does not improve marking efficiency assessed in vivo. *Blood* 89:4040-4046, 1997.
48. Moroff G, **Leitman SF**, Luban NLC. Principles of blood irradiation, dose validation and quality control. *Transfusion* 37:1084-1092, 1997.
49. Brady RO, Murray GJ, **Leitman SF**, Sneller MC, Fleisher TA, Barton NW. Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease. *Pediatrics* 100:E11, 1997.

50. Anderlini P, Korbling M, Dale D, Gratwohl A, Schmitz N, Stroncek D, Howe C, **Leitman SF**, Horowitz M, Gluckman E, Rowley S, Przepiorka D, Champlin R. Allogeneic blood stem cell transplantation: considerations for donors. *Blood* 90:903-908, 1997.
51. Dunbar CE, Kohn DB, Schiffmann R, Barton NW, Nolta JA, Esplin JA, Pensiero M, Long Z, Lockey C, Emmons RV, Csik S, **Leitman SF**, Krebs CB, Carter C, Brady RO, Karlsson S. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: in vivo detection of transduced cells without myeloablation. *Hum Gene Ther* 9:2629-40, 1998.
52. Gordon BR, Kelsey SF, Dau, PC, Gotto AM, Graham K, Illingworth R, Isaacsohn J, Jones PH, **Leitman SF**, Saal SD, Stein EA, Stern TN, Troendle A, Zweiner RJ. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. *Am J Cardiol* 81:407-411, 1998.
53. Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, **Leitman SF**, Klein HG, Mullen CA, Metcalf JA, Baseler M, Falloon J, Davey RT, Kovacs JA, Polis MA, Masur H, Blaese RM, Lane HC. Peripheral expansion of pre-existing mature T cells is an important means of CD4+ T-cell regeneration in HIV-infected adults. *Nat Med* 4:852-856, 1998.
54. McDermott DH, Zimmerman PA, Guignard F, Kleeberger CA, **Leitman SF**, Murphy PM. CCR5 promoter polymorphism and HIV-1 disease progression. Multicenter AIDS Cohort Study (MACS). *Lancet* 352:866-870, 1998.
55. Stroncek DS, **Leitman SF**. Granulocyte transfusions: a review. *Immunohematology* 14:101-108, 1998.
56. Dunbar C, Chang L, Mullen C, Ramsey WJ, Carter C, Kohn D, Parkman R, Lenarsky C, Weinberg K, Wara D, Culver KW, Anderson WF, **Leitman SF**, Fleisher T, Klein H, Shearer G, Clerici M, McGarrity G, Bastian J, Hershfield MS. Amendment to Clinical Research Project. Project 90-C-195. April 1, 1993. Treatment of severe combined immunodeficiency disease (SCID) due to adenosine deaminase deficiency with autologous lymphocytes transduced with a human ADA gene. *Hum Gene Ther* 10:477-8, 1999.
57. Goedert JJ, Sauter ME, Jacobson LP, Vessella RL, Hilgartner MW, **Leitman SF**, Fraser MC, Mueller-Lantzsch NG. High prevalence of antibodies against HERV-K10 in patients with testicular cancer but not with AIDS. *Cancer Epidemiol Biomarkers Prev* 8:293-6, 1999.
58. Liu JM, Kim S, Read EJ, Futaki M, Dokal I, Carter CS, **Leitman SF**, Pensiero M, Young NS, Walsh CE. Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene(FANCC). *Human Gene Ther* 10:2337-2346, 1999.
59. Cowan KH, Moscow JA, Huang H, Zujewski JA, O'Shaughnessy J, Sorrentino B, Hines K, Carter C, Schneider E, Cusack G, Noone M, Dunbar C, Steinberg S, Wilson W, Goldspiel B, Read EJ, **Leitman SF**, McDonagh K, Chow C, Abati A, Chiang Y, Chang YN, Gottesman MM, Pastan I, Nienhuis A. Paclitaxel chemotherapy after autologous stem-cell transplantation and engraftment of hematopoietic cells transduced with a retrovirus containing the multidrug resistance complementary DNA (MDR1) in metastatic breast cancer patients. *Clin Cancer Res* 5:1619-28, 1999.

60. Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G, Chow C, Venzon D, Sorrentino B, Chiang Y, Goldspiel B, **Leitman SF**, Read EJ, Abati A, Gottesman MM, Pastan I, Sellers S, Dunbar C, Cowan KH. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. *Blood* 94:52-61, 1999.
61. Bolan CD, **Leitman SF**. Hematopoietic stem-cell transplantation for acute leukemia. *N Engl J Med.* 340:810, 1999 (letter).
62. Childs R, Clave E, Contentin N, Hensel N, **Leitman SF**, Read EJ, Carter S, Bahceci E, Young NS, Barrett AJ. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. *Blood* 94:3234-3241, 1999.
63. Perlmutter SJ, **Leitman SF**, Garvey MA, Hamburger S, Leonard HL, Swedo SE. Effects of therapeutic plasma exchange and intravenous immunoglobulin for childhood-onset obsessive-compulsive disorder and tic disorders. *Lancet* 354:1153-1158, 1999.
64. Lehrnbecher T, Foster CB, Zhu S, **Leitman SF**, Goldin L, Huppi K, Chanock SJ. Variant genotypes of the low-affinity Fcγ receptors in two control populations and a review of low-affinity Fcγ receptor polymorphisms in control and disease populations. *Blood* 94:4220-4232, 1999.
65. Bahceci E, Read EJ, **Leitman SF**, Childs R, Dunbar C, Young NS, Barrett AJ. CD34+ cell dose predicts relapse and survival after T-cell-depleted HLA-identical haematopoietic stem cell transplantation for haematologic malignancies. *Br J Haematol* 108:408-14, 2000.
66. Stroncek DF, Confer DL, **Leitman SF**. Peripheral blood progenitor cells for HPC transplants involving unrelated donors. *Transfusion* 40:731-741, 2000.
67. Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, Stevens R, Chen CC, **Leitman SF**, Palensky J, Wittes J, Davey RT, Falloon J, Polis MA, Kovacs JA, Broad DF, Levine BL, Roberts MR, Masur H, Lane CL. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. *Blood* 96:467-474, 2000.
68. Lightfoot T, **Leitman SF**, Stroncek DF. Storage of granulocyte colony-stimulating-factor mobilized granulocyte concentrates. *Transfusion* 40:1104-1110, 2000.
69. McDermott DH, Beecroft MJ, Kleeberger CA, Al-Sharif FA, Zimmerman PA, **Leitman SF**, Detels R, Hajeer AH, Murphy PM. Chemokine RANTES promoter polymorphism affects risk of both HIV infection and disease progression in the Multicenter AIDS cohort Study. *AIDS* 14:2671-2678, 2000.
70. McDermott DH, Colla JS, Kleeberger CA, Plankey M, Rosenberg PS, Smith ED, Zimmerman PA, Combadière C, **Leitman SF**, Kaslow RA, Goedert JJ, Berger EA, O'Brien TR, Murphy PM. Genetic polymorphism in CX3CR1 and risk of HIV disease. *Science* 290:2031, 2000.
71. Mackall CL, Stein D, Fleisher TA, Brown MR, Hakim FT, **Leitman SF**, Read EJ, Carter CS, Wexler LH, Gress RE. Prolonged CD4 depletion after sequential autologous peripheral

- blood progenitor cell infusions in children and young adults. *Blood* 96:754-62, 2000.
72. Childs R, Chernoff A, Contentin N, Bahceci E, Schrupp D, **Leitman S**, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. *N Engl J Med* 343:750-758, 2000.
 73. Smith JD, **Leitman SF**. Filtration of RBC units: effect of storage time and temperature on filter performance. *Transfusion* 40:521-526; 2000.
 74. Lightfoot T, Gallelli J, Matsuo K, Kwon SW, **Leitman SF**, Stroncek DF. Evaluation of solutions for the storage of granulocyte colony-stimulating factor-mobilized granulocyte concentrates. *Vox Sanguinis* 2001 Feb; 80:106-111.
 75. Bolan CD, Childs RW, Procter JL, Barrett AJ, **Leitman SF**. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. *Br J Haematol* 2001 Mar; 112:787-795.
 76. Horwitz ME, Barrett AJ, Holland SM, Childs R, Miller JA, **Leitman SF**, Read EJ, Carter CS, Brown MR, Gallin JI, Malech HL. Allogeneic stem cell transplantation for chronic granulomatous disease using low intensity marrow conditioning and T-cell depletion of the allograft. *N Engl J Med* 2001 Mar; 344:881-888.
 77. Lazarus EF, Browning J, Norman J, Oblitas J, **Leitman SF**. Sustained decreases in platelet count associated with multiple regular, plateletpheresis donations. *Transfusion* 2001 Jun; 41:756-761.
 78. Bolan CD, Conry-Cantilena C, Mason G, Rouault TA, **Leitman SF**. MCV as a guide to phlebotomy therapy for hereditary hemochromatosis. *Transfusion* 2001 Jun; 41:819-827.
 79. Stroncek DF, Procter JL, Moses L, Bolan CD, Pomper P, Conry-Cantilena C, Malech H, **Leitman SF**. Intravenous Rh immune globulin prevents alloimmunization in D-negative granulocyte recipients, but obscures the detection of an alloanti-K. *Immunohematology* 2001 Jun;17:37-41.
 80. Dudley ME, Wunderlich J, Nishimura MI, Yu D, Yang JC, Topalian SL, Schwartzentruber DJ, Hwu P, Marincola FM, Sherry R, Leitman SF, Rosenberg SA. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. *J Immunotherapy* 2001 Jul-Aug; 24:363-373.
 81. Stroncek DF, Yau YY, Oblitas J, **Leitman SF**. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. *Transfusion* 2001 Aug; 41:1037-1044.
 82. Bolan CD, Greer SE, Cecco SA, Oblitas JM, Rehak NN, **Leitman SF**. Comprehensive analysis of citrate effects during plateletpheresis in normal donors. *Transfusion* 2001 Sep; 41:1165-1171.
 83. Bolan CD, **Leitman SF**, Griffith LM, Wesley RA, Procter JL, Stroncek DF, Barrett AJ, Childs RW. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-

- incompatible nonmyeloablative hematopoietic stem cell transplantation. *Blood* 2001 Sep; 98:1687-1694.
84. Kondo T, Cortese I, Markovic-Plese S, Wandinger KP, Carter C, Brown M, **Leitman SF**, Martin R. Dendritic cells signal T cells in the absence of exogenous antigen. *Nature Immunol* 2001 Oct; 2:932-938.
 85. Nakamura R, Bahceci E, Read EJ, **Leitman SF**, Carter CS, Childs R, Dunbar CE, Gress R, Altemus R, Young NS, Barrett AJ. Transplant dose of CD34+ and CD3+ cells predicts outcome in patients with haematological malignancies undergoing T cell-depleted peripheral blood stem cell transplants with delayed donor lymphocyte add-back. *Brit J Haematol* 2001 Oct; 115:95-104.
 86. Shi PA, Pomper GJ, Metzger ME, Donahue RE, **Leitman SF**, Dunbar CE. Assessment of rapid remobilization intervals with G-CSF and SCF in murine and rhesus macaque models. *Transfusion* 2001 Nov; 41:1438-1444.
 87. Bolan CD, Oral EA, Gorden P, Taylor S, **Leitman SF**. Intensive, long-term plasma exchange therapy for severe hypertriglyceridemia in acquired generalized lipoatrophy. *J Clin Endocrinol Metab* 2002 Jan; 87:380-384.
 88. Kang EM, de Witte M, Malech H, Morgan RA, Phang S, Carter C, **Leitman SF**, Childs R, Barrett AJ, Little R, Tisdale JF. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency syndrome. *Blood* 2002 Jan; 99:698-701.
 89. Kang EM, Areman EA, David-Ocampo V, Fitzhugh C, Link ME, Read EJ, **Leitman SF**, Rodgers GP, Tisdale JF. Mobilization, collection and processing of peripheral blood progenitor cells in individuals with sickle cell trait. *Blood* 2002 Feb; 99:850-5.
 90. Dagher R, Long L, Read EJ, **Leitman SF**, Carter CS, Tsokos M, Goletz TZ, Avila N, Berzovsky JA, Helman LJ, Mackall CL. Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma. *Med Pediatr Oncol* 2002 Mar; 38:158-164.
 91. Bolan CD, **Leitman SF**. Management of anticoagulation-associated toxicity during large-volume leukapheresis of peripheral blood stem cell donors. *Blood* 2002 Mar; 99:1878.
 92. Stroncek DS, Matthews CL, Follman D, **Leitman SF**. Kinetics of G-CSF-induced granulocyte mobilization in healthy subjects: effects of route of administration and addition of dexamethasone. *Transfusion* 2002 May; 42:597-602.
 93. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, **Leitman SF**, Seipp CA, Morton KE, Nahvi A, White DE, Rosenberg SA. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. *J Immunotherapy* 2002 May-Jun; 25:243-251.

94. Bolan CD, Cecco SA, Wesley RA, Horne M, Yau YY, Remaley AT, Childs RW, Barrett AJ, Rehak NN, **Leitman SF**. Controlled study of citrate effects and response to IV calcium administration during allogeneic peripheral blood progenitor cell donation. *Transfusion* 2002 July; 42: 935-946.
95. Kang EM, De Witte M, Malech H, Morgan RA, Carter C, **Leitman SF**, Childs R, Barrett AJ, Little R, Tisdale JF. Gene therapy-based treatment for HIV-positive patients with malignancies. *J Hematother Stem Cell Res* 2002 Oct; 11:809-16.
96. Stroncek DF, Rainer T, Sharon V, Byrne KM, Noguchi CT, Klein HG, Schechter AN, **Leitman SF**. Sick cell Hb polymerization in RBC components from donors with sickle cell trait prevents effective WBC reduction by filtration. *Transfusion* 2002 Nov; 42:1466-72.
97. Taylor JG, Tang DC, Savage SA, **Leitman SF**, Heller SI, Serjeant GR, Rodgers GP, Chanock SJ. Variants in the *VCAM1* gene and risk for symptomatic stroke in sickle cell disease. *Blood* 2002 Dec 15; 100:4303-9.
98. Bolan CD, Carter CS, Wesley RA, Yau YY, Barrett AJ, Childs RW, Read EJ, **Leitman SF**. Prospective evaluation of cell kinetics, yields and donor experiences during a single large volume apheresis versus two smaller volume consecutive day collections of allogeneic peripheral blood stem cells. *Brit J Hematol* 2003 Mar; 120:801-807.
99. Muul LM, Tuschong LM, Soenen SL, Jagadeesh GJ, Ramsey WJ, Long Z, Carter CS, Garabedian EK, Brown M, Bernstein W, Schurman SH, Fleisher TA, **Leitman SF**, Dunbar CE, Blaese M, Candotti F. Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. *Blood* 2003 Apr; 101:2563-2569.
100. Moncada V, Bolan CD, Yau YY, **Leitman SF**. Analysis of PBPC cell yields during large-volume leukapheresis of subjects with a poor mobilization response to filgrastim. *Transfusion* 2003 Apr; 43:495-501.
101. Solomon SR, Nakamura R, Read EJ, **Leitman SF**, Carter C, Childs R, Dunbar CE, Young NS, Barrett AJ. Cyclosporine is required to prevent severe acute GVHD following T-cell-depleted peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 2003 May; 31:783-8.
102. Stroncek D, Shawker T, Follmann D, **Leitman SF**. G-CSF-induced spleen size changes in peripheral blood progenitor cell donors. *Transfusion* 2003 May; 43:609-13.
103. Byrne KM, **Leitman SF**, Schechter AN, Stroncek DF. Increasing oxygen tension improves filtration of sickle trait donor blood. *Brit J Hematol* 2003 Aug; 122:678-81.
104. Bolan CD, Wesley RA, Yau YY, Cecco SA, Starling J, Oblitas JM, Rehak NN, **Leitman SF**. Randomized placebo-controlled study of oral calcium carbonate administration in plateletpheresis: I. Associations with donor symptoms. *Transfusion* 2003 Oct; 43:1403-1413.

105. Bolan CD, Cecco SA, Yau YY, Wesley RA, Oblitas JM, Rehak NN, **Leitman SF**. Randomized placebo-controlled study of oral calcium carbonate supplementation in plateletpheresis: II. Metabolic effects. *Transfusion* 2003 Oct; 43:1414-1422.
106. Pomper GJ, Rick ME, Epstein JS, Read EJ, **Leitman SF**. Management of severe von Willebrand's disease with cryoprecipitate collected by repeated apheresis of a single dedicated donor. *Transfusion* 2003 Nov;43:1514-21.
107. **Leitman SF**, Browning JN, Yau YY, Mason G, Klein HG, Conry-Cantilena C, Bolan CD. Impact of using hemochromatosis subjects as allogeneic blood donors: a prospective study. *Transfusion* 2003 Nov; 43:1538-1544.
108. **Leitman SF**, Tisdale JF, Bolan CD, Popovsky MA, Klippel JH, Balow JE, Boumpas DT, Illei GG. Transfusion-associated GVHD after fludarabine therapy in a patient with systemic lupus erythematosus *Transfusion* 2003 Dec; 43:1667-1671.
109. Moir S, Donoghue ET, Pickeral OK, Malaspina A, Planta MA, Chun TW, Krishnan SR, Kottlil S, Birse CE, **Leitman SF**, Fauci AS. Continuous flow leukapheresis induces expression of stress genes in lymphocytes; impact on microarray analyses. *Blood* 2003 Nov 15;102:3852-3.
110. Bolan CD, Yau YY, Cullis HC, Horwitz ME, Mackall, CL, Barrett AJ, Malech HL, Rehak NN, Wayne AS, **Leitman SF**. Pediatric large volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens. *Transfusion* 2004 Feb;44:229-238.
111. Rick ME, Austin H, **Leitman SF**, Krizek DM, Aronson DL. Clinical usefulness of a functional assay for the von Willebrand Factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura. *Am J Hematol* 2004 Feb;75:96-100.
112. Yamashita K, Choi U, Woltz PC, Foster S, Sneller MC, Hakim F, Fowler D, Bishop M, Pavletic SZ, Tamari M, Castro K, Barrett AJ, Childs R, Illei G, **Leitman SF**, Malech HL, Horwitz M. Severe chronic graft-versus-host-disease is characterized by a preponderance of CD4⁺ effector memory cells relative to central memory cells. *Blood* 2004 May 15; 103:3986-8.
113. Stroncek DF, Dittmar K, Shawker T, Heatherman A, **Leitman SF**. Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF. *J Translational Med* 2004 Jul; 2:25.
114. Saif MW, **Leitman SF**, Cusack G, Horne M, Freifeld A, Venzon D, PremKumar A, Cowan, KH, Gress RE, Zujewski J, Kasten-Sportes C. Thromboembolism following removal of femoral venous apheresis catheters in patients with breast cancer. *Ann Oncol* 2004 Sep; 15:1366-1372.
115. Bishop MR, Steinberg SM, Gress R, Hardy NM, Marchigiani D, Kasten-Sportes C, Dean R, Pavletic SZ, Castro K, Hakim F, Read EJ, Carter S, **Leitman SF**, Fowler DH. Targeted pretransplant host lymphocyte depletion prior to T-cell depleted reduced-intensity allogeneic stem cell transplantation. *Br J Hematol* 2004 Sep;126:837-843.

116. Stroncek DF, Byrne KM, Noguchi CT, Schechter AN, **Leitman SF**. Increasing hemoglobin oxygen saturation levels in sickle trait donor whole blood prevents hemoglobin S polymerization and allows effective leukocyte reduction by filtration. *Transfusion* 2004 Sep; 44:1293-99.
117. **Leitman SF**, Bolan CD, Klein HG. Red cells from hemochromatosis donors. Marginalized, but hardly marginal. Letter. *Transfusion* 2004 Oct; 44:1537-38.
118. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten-Sportes C, Steinberg S, Gea-Banacloche JC, Dean R, Chow CK, Carter C, Read EJ, **Leitman SF**, Gress R. Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. *J Clin Oncol* 2004 Oct; 22:3886-92.
119. Stevens WT, Pittaluga S, Dunleavy K, Wilson WH, **Leitman SF**, Bolan CD. Hemophagocytosis and coagulopathy associated with cutaneous gamma-delta T-cell lymphoma. *Transfusion* 2004 Dec; 44:1679.
120. Powell TM, Paul JD, Hill JM, Thompson M, Benjamin M, Rodrigo M, McCoy JP, Read EJ, Khuu HM, **Leitman SF**, Finkel T, Cannon RO. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. *Arterioscler Thromb Vasc Biol* 2005 Feb; 25:296-301.
121. Griffith LM, McCoy JP, Bolan CD, Stroncek DF, Pickett AC, Linton GF, Lundqvist A, Srinivasan R, **Leitman SF**, Childs RW. Persistence of recipient plasma cells and anti-donor isohemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. *Br J Haematol* 2005 Mar;128:668-75.
122. Solomon SR, Mielke S, Savani BN, Montero A, Wisch L, Childs R, Hensel N, Schindler J, Ghetie V, **Leitman SF**, Mai T, Carter CS, Kurlander R, Read EJ, Vitetta ES, Barrett AJ. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. *Blood* 2005 Aug;106:1123-9.
123. Garvey MA, Snider LA, **Leitman SF**, Werden R, Swedo SE. Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone. *J Child Neurol*. 2005 May;20:424-9.
124. Tudisco C, Jett BW, Byrne K, Oblitas J, **Leitman SF**, Stroncek DF. The value of pH as a quality control indicator for apheresis platelets. *Transfusion* 2005 May;45:773-8.
125. Pittman PR, **Leitman SF**, Barrera-Oro JG, Norris SL, Marano NM, Ranadive MV, Sink BS, McKee KT. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. *Clin Diag Lab Immunol* 2005 Jun;12:713-21.
126. Haddad S, **Leitman SF**, Wesley RA, Cecco S, Yau YY, Starling J, Rehak NN, Bolan CD. Randomized placebo-controlled study of intravenous magnesium supplementation during large volume leukapheresis in healthy allogeneic donors. *Transfusion* 2005 Jun;45:934-44.

127. Patel HD, Byrne KM, Horne M, Leitman SF, Stroncek DF. Factors affecting the formation of white particulate matter in red blood cell components. *Transfusion* 2005 Jul;45:1127-32.
128. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, Metcalf JA, Davey R, Falloon J, Polis M, Tavel J, Stevens R, Fox S, Leitman SF, Baseler MW, Masur H, Dimitrov DS, Lane HC. Induction of prolonged survival of CD4+ T lymphocytes by intermittent IL-2 therapy in patients with HIV infection. *J Clin Invest* 2005 Aug; 15:2139-48.
129. Solomon SR, Savani BN, Childs R, Montero A, Boss C, Read EJ, Leitman SF, Barrett AJ. Improved outcome for peripheral blood stem cell transplantation for advanced primary myelodysplastic syndrome. *Biol Blood Marrow Transplant* 2005 Aug;11:619-26.
130. Morgan RA, Walker R, Carter CS, Natarajan V, Tavel JA, Bechtel C, Herpin B, Muul L, Zheng Z, Jagannatha S, Bunnell BA, Fellowes V, Metcalf JA, Stevens R, Baseler M, Leitman SF, Read EJ, Blaese RM, Lane HC. Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals. *Hum Gene Therapy* 2005 Sep;16:1065.
131. Montero A, Savani BN, Kurlander R, Read EJ, Leitman SF, Childs R, Solomon SR, Barrett AJ. Lineage-specific engraftment and outcomes after T-cell-depleted peripheral blood stem cell transplant with Flu/Cy/TBI conditioning. *Br J Haematol* 2005 Sep;130:733-9.
132. Leitman SF. Progenitor cell mobilization gets a boost from CXCR4 inhibition. *Blood* 2005 Sep;106:1-2.
133. Hill JM, Syed MA, Arai AE, Powell TM, Paul JD, Zalos G, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Waclawiw MA, Cannon RO. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. *J Am Coll Cardiol*. 2005 Nov; 46:1643-8.
134. Stroncek D, Slezak S, Khuu H, Basil C, Tisdale J, Leitman SF, Marincola FM, Panelli MC. Proteomic signature of myeloproliferation and neutrophilia: analysis of serum and plasma from healthy subjects given granulocyte colony-stimulating factor. *Exp Hematol*. 2005 Oct; 33:1109-17.
135. Yamashita K, Horwitz ME, Kwatema A, Nomicos E, Castro K, Sokolic R, Foster SF, Garofalo M, Choi U, Ryherd M, Brown MR, Leitman SF, Wayne AS, Fowler DH, Bishop MR, Childs RW, Barrett AJ, Pavletic SZ, Malech HL. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis. *Biol Blood Marrow Transplant*. 2006 Jan;12:22-30.
136. Nambiar A, Duquesnoy R, Adams S, Zhao Y, Oblitas J, Leitman S, Stroncek D, Marincola F. HLA Matchmaker-driven analysis of responses to HLA-typed platelet transfusions in alloimmunized thrombocytopenic patients. *Blood* 2006 Feb 15;105:1680-1687.
137. Savani BN, Rezvani K, Mielke S, Montero A, Kurlander R, Carter CS, Leitman SF, Read EJ, Childs R, Barrett AJ. Factors associated with early molecular remission following T cell depleted allogeneic stem cell transplantation for chronic myelogenous leukemia. *Blood* 2006 Feb 15;105:1688-1695.

138. Stevens WT, Bolan CD, Oblitas JM, Bennett JE, Stroncek DF, Leitman SF. *Streptococcus agalactiae* sepsis following transfusion of a plateletpheresis concentrate: benefit of donor evaluation. *Transfusion* 2006 Apr;46:649-51.
139. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Smith KP, Sachdev V, Birdsall CW, Sidenko S, Waclawiw MA, Leitman SF, Rosing DR. Left ventricular systolic function during stress echocardiography exercise in subjects with asymptomatic hereditary hemochromatosis. *Am J Cardiol* 2006 Sept;98:694-8.
140. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Nguyen TT, Botello G, Sachdev V, Sidenko S, Ernst I, Waclawiw MA, Leitman SF, Rosing DR. Significance of left atrial contractile function in asymptomatic subjects with hereditary hemochromatosis. *Am J Cardiol* 2006 Oct; 98:954-9.
141. Ayache S, Panelli MC, Byrne KM, Slezak S, Leitman SF, Marincola FM, Stroncek DF. Comparison of proteomic profiles of serum, plasma, and modified media supplements used for cell culture and expansion. *J Transl Med* 2006 Oct 4;4:40.
142. Fowler DH, Odom J, Steinberg SM, Chow CK, Foley J, Kogan Y, Hou J, Gea-Banacloche J, Sportes C, Pavletic S, Leitman S, Read EJ, Carter C, Kolstad A, Fox R, Beatty GL, Vonderheide RH, Levine BL, June CH, Gress RE, Bishop MR. Phase I clinical trial of costimulated, IL-4 polarized donor CD4+ T cells as augmentation of allogeneic hematopoietic cell transplantation. *Biol Blood Marrow Transplant* 2006 Nov;12:1150-60.
143. Montero A, Savani BN, Shenoy A, Read EJ, Carter CS, Leitman SF, Mielke S, Rezvani K, Childs R, Barrett AJ. T-cell depleted peripheral blood stem cell allotransplantation with T cell add back for patients with hematological malignancies: effect of chronic GVHD on outcome for patients with hematological malignancies. *Biol Blood Marrow Transplant* 2006 Dec;12:1318-25.
144. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Smith KP, Arena R, Waclawiw MA, Leitman SF, Rosing DR. Exercise capacity of cardiac asymptomatic hereditary hemochromatosis subjects. *Med Sci Sports Exerc* 2007 Jan; 39:3-7.
145. Fadeyi EA, De Los Angeles Muniz M, Wayne AS, Klein HG, Leitman SF, Stroncek DF. The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. *Transfusion* 2007 Mar;47:545-50.
146. Shizukuda Y, Bolan CD, Nugyen TT, Botello G, Tripodi DJ, Yau YY, Waclawiw MA, Leitman SF, Rosing RR. Oxidative stress in asymptomatic subjects with hereditary hemochromatosis. *Am J Hematol* 2007 Mar;82:249-250.
147. Allison RD, Bryant BJ, Vasu S, Leitman SF. Iron reduction and cardiovascular outcomes. *J Am Med Assoc* 2007 May; 297:2075 (letter).
148. Arena R, Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Smith KP, Waclawiw MA, Leitman SF, Rosing DR. Heart rate recovery is lower following supine exercise in asymptomatic hereditary hemochromatosis subjects compared with healthy controls. *J Cardiopulm Rehabil Prev* 2007 Jun; 27:157-160.

149. Provenzano M, Selleri S, Jin P, Wang E, Werden R, Slezak S, Adams SD, Panelli MC, Leitman SF, Stroncek DF, Marincola FM. Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals. *Cancer Immunol Immunother* 2007 Jul; 56:1047-1063.
150. Sloand EM, Read EJ, Scheinberg P, Tang Y, More K, Leitman SF, Maciejewski J, Young NS. Mobilization, collection, and immunomagnetic selection of peripheral blood CD34 cells in recovered aplastic anemia patients. *Transfusion* 2007 Jul;47:1250-1253.
151. Tanno T, Bhanu NV, ONeal PA, Goh SH, Staker P, Lee YT, Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs R, Ganz T, Leitman SF, Fucharoen S, Miller JL. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. *Nat Med* 2007 Sep; 13:1096-1101.
152. Bryant BJ, Cantilena CC, Ahlgren A, Felice A, Stroncek DF, Gible J, Leitman SF. *Pasteurella multocida* bacteremia in asymptomatic plateletpheresis donors: a tale of two cats. *Transfusion* 2007 Nov;47:1984-1989.
153. Bryant BJ, Bianchi M, Wesley RA, Stroncek DF, Leitman SF. Leukoreduction filtration of whole blood units from sickle trait donors: effects of a metered citrate anticoagulant system. *Transfusion* 2007 Dec;47:2233-41.
154. Muniz M, Sheldon S, Schuller RM, Young, NS, Klein HG, Leitman SF, Stroncek DF. Patient-specific transfusion-related acute lung injury. *Vox Sanguinis* 2008 Jan; 94:70–73
155. Fadeyi EA, Adams S, Sheldon S, Leitman SF, Wesley R, Klein HG, Stroncek DF. A preliminary comparison of the prevalence of transfusion reactions in recipients of platelet components from donors with and without human leucocyte antigen antibodies. *Vox Sanguinis* 2008 May; 94: 324-8.
156. Fadeyi E, Adams S, Peterson B, Hackett J, Byrne P, Klein HG, Marincola FM, Leitman SF, Stroncek DF. Analysis of a high-throughput HLA antibody screening assay for use with platelet donors. *Transfusion* 2008 Jun; 48:1174-9.
157. Cirino CM, Leitman SF, Williams E, Fedorko D, Palmore TN, Klion A, Ockenhouse C, Fitzhugh C, Tisdale JF, Hsieh MM. Transfusion-associated babesiosis with an atypical time course after nonmyeloablative transplantation for sickle cell disease. *Ann Intern Med* 2008 May 20; 148:794-5.
158. de Silva R, Raval AN, Hadi M, Gildea KM, Bonifacino AC, Yu ZX, Yau YY, Leitman SF, Bacharach SL, Donahue RE, Read EJ, Lederman RJ. Intracoronary infusion of autologous mononuclear cells from bone marrow or granulocyte colony-stimulating factor-mobilized apheresis product may not improve remodelling, contractile function, perfusion, or infarct size in a swine model of large myocardial infarction. *Eur Heart J* 2008 Jul ; 29:1772-82.
159. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ. A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. *Clin Cancer Res.* 2008 Aug;14:4850-8.

160. Vasu S, Leitman SF, Tisdale JF, Hsieh MM, Childs RW, Barrett AJ, Fowler DH, Bishop MR, Kang EM, Malech HL, Dunbar CE, Khuu HM, Wesley R, Yau YY, Bolan CD. Donor demographic and laboratory predictors of allogeneic peripheral blood stem cell mobilization in an ethnically diverse population. *Blood* 2008 Sep;112:2092-100.
161. Wang JK, Sheldon SL, Klein HG, Leitman SF, Stroncek DF. Sporadic leukocyte reduction filter failure during RBC component preparation: beware of rapid filtration. *Transfusion* 2008 Aug;48:1766-7.
162. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang JP, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey S, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. *J Clin Oncol* 2008 Nov;26:5233-9.
163. Quillen K, Yau YY, Leitman SF. The determinants of granulocyte yield in 1198 granulocyte concentrates collected from unrelated volunteer donors mobilized with dexamethasone and granulocyte-colony-stimulating factor: a 13-year experience. *Transfusion* 2009 Mar;49:421-6.
164. Quillen K, Byrne P, Yau YY, Leitman SF. Ten-year follow-up of unrelated volunteer granulocyte donors who have received multiple cycles of granulocyte-colony-stimulating factor and dexamethasone. *Transfusion* 2009 Mar;49:513-8.
165. Pulsipher MA, Chitphakdithai P, Miller JP, Logan BR, King RJ, Rizzo JD, Leitman SF, Anderlini P, Haagenson MD, Kurian S, Klein JP, Horowitz MM, Confer DL. Adverse events among 2408 unrelated donors of peripheral blood stem cells: results of a prospective trial from the National Marrow Donor Program. *Blood* 2009 Apr;113:3604-11.
166. Bryant BJ, **Leitman SF**, Klein HG. Therapeutic plasma exchange reveals a color-coordinated response to cyclosporine-induced microangiopathic hemolytic anemia and rifampin after stem cell transplant. *Transfusion* 2009 Jul;49:1291-2.
167. Daniel-Johnson J, **Leitman SF**, Klein HG, Alter HJ, Lee-Stroka A, Scheinberg P, Pantin J, Quillen KQ. Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. *Transfusion* 2009 Sep;49:1845-9.
168. Bryant BJ, Hopkins JA, Arceo SM, **Leitman SF**. Evaluation of low red blood cell mean corpuscular volume in an apheresis donor population. *Transfusion* 2009 Sep;49:1971-6.
169. Powers ML, Lublin D, Eby C, **Leitman SF**, Dynis M, Despotis GJ. Safety concerns related to use of unapproved needles for accessing implantable venous access devices. *Transfusion*. 2009 Sep; 49:2008-9.
170. Pulsipher MA, Chitphakdithai P, Logan BR, **Leitman SF**, Anderlini P, Klein JP, Horowitz MM, Miller JP, King RJ, Confer DL. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. *Blood* 2009 Sep;114:2606-16.

171. Shizukuda Y, Bolan CD, Tripodi DJ, Sachdev V, Nguyen TT, Botello G, Yau YY, Sidenko S, Inez E, Ali MI, Waclawiw MA, **Leitman SF**, Rosing DR. Does oxidative stress modulate left ventricular diastolic function in asymptomatic subjects with hereditary hemochromatosis? *Echocardiography* 2009 Nov; 26:1153-8.
172. Quillen K, Wong E, Scheinberg P, Young NS, Walsh TJ, Wu CO, **Leitman SF**. Granulocyte transfusions in severe aplastic anemia: an eleven-year experience. *Haematologica* 2009 Dec; 94:1661-8.
173. Pos Z, Selleri S, Spivey TL, Wanf JK, Liu H, Worschech A, Sabatino M, Monaco A, **Leitman SF**, Falus A, Wang E, Alter HJ, Marincola FM. Genomic scae analysis of racial impact on response to IFN- α . *Proc Nat Acad Sci* 2010 Jan;107:803-8.
174. Bryant BJ, Yau YY, Byrne PJ, Stroncek DF, **Leitman SF**. Gravity sedimentation of granulocytopheresis concentrates with hydroxyethyl starch efficiently removes red blood cells and retains neutrophils. *Transfusion*. 2010 Jun; 50:1203-09.
175. Tanno T, Rabel A, Lee YT, Yau YY, **Leitman SF**, Miller JL. Expression of growth differentiation factor 15 is not elevated in individuals with iron deficiency secondary to volunteer blood donation. *Transfusion* 2010 Jul; 50:1532-35.
176. O'Donnell PV, Pedersen TL, Confer DL, Rizzo JD, Pulsipher MA, Stroncek D, **Leitman S**, Anderlini P; Donor Health and Safety Working Committee from Center for International Blood and Marrow Transplant Research (CIBMTR). Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. *Blood*. 2010 Jun 17;115:5097-101.
177. Quillen K, Medrano C, Adams S, Peterson B, Hackett J, **Leitman SF**, Klein HG, Stroncek DF. Screening plateletpheresis donors for HLA antibodies on two high-throughput platforms and correlation with recipient outcome. *Transfusion* 2011 Mar;51:504-10.
178. Clayton JA, Vitale S, Kim J, Cantilena CC, Byrne P, Reed GF, Ferris FL, **Leitman SF**. Prevalence of posterior subcapsular cataracts in volunteer cytopheresis donors. *Transfusion* 2011 May; 51:921-8.
179. Strauss RG, Klein HG, **Leitman SF**, Price TH, Lichtiger B, Martinez F, Reesink HW, Panzer S. Preparation of granulocyte concentrates by apheresis: collection modalities in the USA. *Vox Sang* 2011 May;100:426-433.
180. Heim KF, Fleisher TA, Stroncek DF, Holland SM, Malech HL, **Leitman SF**. The relationship between alloimmunization and post-transfusion granulocyte survival: experience in a chronic granulomatous disease cohort. *Transfusion* 2011 Jun; 51:1154-62.
181. Uchida N, Bonifacino A, Krouse AE, Metzger ME, Csako G, Lee-Stroka A, Fasano RM, **Leitman SF**, Hsieh MM, Tisdale JF, Donahue RE. Accelerated lymphocyte reconstitution and long-term recovery following transplantation of transduced rhesus CD34+ cells mobilized by G-CSF and plerixafor. *Exp Hematol* 2011;39:795-805.
182. Donahue RE, Tuschong L, Bauer TR, Yau YY, **Leitman SF**, Hickstein DD. Leukocyte integrin activation mediates transient neutropenia following G-CSF administration. *Blood*

2011 Oct 13;118:4209-4214.

183. McIver Z, Melenhorst JJ, Grim A, Naguib N, Weber G, Fellowes V, Khuu H, Stroncek DS, **Leitman SF**, Battiwalla M, John Barrett A. Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplants: T cell subset frequencies predict outcome. *Biol Blood Marrow Transplant*. 2011 Dec;17:1846-1854.
184. Mielke S, McIver ZA, Shenoy A, Fellowes V, Khuu H, Stroncek DF, **Leitman SF**, Childs R, Battiwalla M, Koklanaris E, Haggerty J, Savani B, Rezvani K, JohnBarrett A. Selectively T cell-depleted allografts from HLA-matched sibling donors followed by low-dose posttransplant immunosuppression to improve transplant outcome in patients with hematologic malignancies. *Biol Blood Marrow Transplant*. 2011 Dec;17:1855-1861.
185. Shizukuda Y, Smith KP, Tripodi DJ, Arena R, Yau YY, Bolan CD, Waclawiw MA, **Leitman SF**, Rosing DR. Changes in left ventricular diastolic function of asymptomatic hereditary hemochromatosis subjects during 5 years of follow-up. *Am J Cardiol*. 2011 Dec 15; 108:1796-1800.
186. O'Donoghille D, Childs RW, **Leitman SF**. Blood consult: granulocyte transfusions to treat invasive aspergillosis in a patient with severe aplastic anemia awaiting mismatched hematopoietic stem cell transplantation. *Blood* 2012 Feb 9;119:1353-1355.
187. Shizukuda Y, Tripodi DJ, Zalos G, Bolan CD, Yau YY, **Leitman SF**, Waclawiw MA, Rosing DR. Incidence of cardiac arrhythmias in asymptomatic hereditary hemochromatosis subjects with C282Y homozygosity. *Am J Cardiol* 2012 Mar 15;109:856-860.
188. Olnes MJ, Poon A, Miranda SJ, Pfannes L, Tucker Z, Loeliger K; Padilla-Nash H. Yau YY, Reid T, **Leitman SF**, Young NS, Sloand EM. Effects of granulocyte-colony-stimulating factor on monosomy 7 aneuploidy in healthy hematopoietic stem cell and granulocyte donors. *Transfusion* 2012 Mar; 52:537-541.
189. Shizukuda Y, Smith KP, Tripodi DJ, Arena R, Yau YY, Bolan CD, Waclawiw MA, **Leitman SF**, Rosing DR. Changes in exercise capacity in subjects with cardiac asymptomatic hereditary hemochromatosis during a follow-up after 5 years. *Am J Phys Med Rehabil*. 2012 May; 91:418-424.
190. Bryant BJ, Yau YY, Arceo SM, Daniel-Johnson J, Hopkins JA, **Leitman SF**. Iron replacement therapy in the routine management of blood donors. *Transfusion* 2012 Jul; 52: 1566-1575.
191. Gulley JL, **Leitman SF**, Dahut W, Schlom J. Response to the safety concerns of leukapheresis and the pitfalls of subset analysis in the Sipuleucel-T trial in castration-resistant prostate cancer. *J Nat Cancer Inst* 2012 Jul;104:1106.
192. Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, McCarthy JM, Khan SP, Anderlini P, Bensinger WI, **Leitman SF**, Rowley SD, Carter SL, Horowitz MM, Confer DL. Peripheral blood stem cells versus bone marrow from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network protocol 0201, a phase III, prospective, randomized trial. *N Engl J Med* 2012 Oct 18; 367:1487-96.

193. Pulsipher MA, Chitphakdithai P, Logan BR, Shaw BE, Wingard JR, Lazarus HM, Waller EK, Seftel M, Stroncek DF, Lopez AM, Maharaj D, Hematti P, O'Donnell PV, Loren AW, **Leitman SF**, Anderlini P, Goldstein SC, Levine JE, Navarro WH, Miller JP, Confer DL. Acute toxicities of unrelated bone marrow versus peripheral blood stem cell donors: results of a prospective trial from the NMDP. *Blood* 2013 Jan 3;121:197-206.
194. Fowler DH, Mossoba ME, Steinberg SM, Halverson DC, Stroncek D, Khuu HM, Hakim FT, Castiello L, Sabatino M, **Leitman SF**, Mariotti J, Gea-Banacloche JC, Sportes C, Hardy NM, Hickstein DD, Pavletic SZ, Rowley S, Goy A, Donato M, Korngold R, Pecora A, Levine BL, June CH, Gress RE, Bishop MR. Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation. *Blood* 2013 Apr 11;121:2864-74.
195. Patel AJ, Wesley R, **Leitman SF**, Bryant BJ. Capillary versus venous hemoglobin determination in the assessment of healthy blood donors. *Vox Sang* 2013 May;104:317-23.
196. Tholpady A, Chiose I, Lyons JL, Baird K, **Leitman SF**. Systemic hypersensitivity reaction mimicking anaphylaxis after first filgrastim administration in a healthy donor. *Transfusion* 2013 May; 53:1146-7.
197. Panch S, Riordan MM, **Leitman SF**. Intermittent leukocytosis in an asymptomatic platelet donor. *Transfusion* 2013 May; 53:1144-6.
198. Bat T, **Leitman SF**, Calvo KR, Chauvet D, Dunbar CE. Measurement of the absolute immature platelet number reflects marrow production and is not impacted by platelet transfusion. *Transfusion* 2013 Jun; 53:1201-4.
199. Bryant BJ, Yau YY, Arceo SM, Hopkins JA, **Leitman SF**. Ascertainment of iron deficiency and depletion in donors through screening questions for pica and restless legs syndrome. *Transfusion* 2013 Aug; 53:1637-44.
200. Pantin J, Tian X, Shah AA, Kurlander R, Ramos C, Cook L, Khuu H, Stroncek D, **Leitman SF**, Barrett AJ, Young NS, Geller N, Childs RW. Rapid donor T-cell engraftment increases the risk of chronic graft-versus-host disease following salvage allogeneic peripheral blood stem cell transplantation for bone marrow failure syndromes. *Am J Hematol.* 2013 Oct; 88:874-82.
201. Lundqvist A, Smith AL, Takahashi Y, Wong S, Bahceci E, Cook L, Ramos C, Tawab A, McCoy JP, Read EJ, Khuu HM, Bolan CD, Joo J, Gellar N, **Leitman SF**, Calandra G, Dunbar C, Kurlander R, Childs RW. Differences in the phenotype, cytokine gene expression profiles and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. *J Immunol* 2013 Dec 15;191:6241-6249.
202. Switzer GE, Bruce JG, Harrington D, Haagenson M, Drexler R, Foley A, Confer D, Bishop M, Anderlini P, Rowley S, **Leitman SF**, Anasetti C, Wingard JR. Health-related quality of life of bone marrow versus peripheral blood stem cell donors: a pre-specified subgroup analysis from a phase III RCT - BMTCTN protocol 0201. *Biol Blood Marrow Transplant* 2014 Jan; 20:118-127.

203. Wang X, Mendelsohn L, Rogers H, **Leitman SF**, Raghavachari N, Yang Y, Yau YY, Tallack M, Perkins A, Taylor JG, Noguchi CT, Kato GJ. Heme-bound iron activates placenta growth factor in erythroid cells via Erythroid Krüppel-like Factor. *Blood* 2014 Aug 7;124:946-54.
204. West KA, **Leitman SF**, Flegel WA. Transfusion medicine illustrated: Muddy waters in therapeutic plasma exchange. *Transfusion* 2014 Sep; 54:2157.
205. Panch SR, Yau YY, Kang EM, De Ravin SS, Malech HL, **Leitman SF**. Mobilization characteristics and strategies to improve hematopoietic progenitor cell mobilization and collection in patients with chronic granulomatous disease and severe combined immunodeficiency. *Transfusion* 2015 Feb; 55:265-74.
206. Panch SR, Yau YY, West K, Diggs K, Sweigart T, **Leitman SF**. Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload. *Transfusion* 2015 Mar; 55:611-22.
207. Kadri S, Remy K, Strich J, Gea-Banacloche J, **Leitman SF**. Role of granulocyte transfusions in invasive fusariosis: systematic review and single center experience. *Transfusion* 2015 Sep; 55:2076-85
208. Gulley JL, Marté J, Heery CR, Madan RA, Steinberg SM, **Leitman SF**, Tsang KY, Schlom J. The impact of leukapheresis on immune cell number and function in patients with advanced cancer. *Cancer Immunol Immunother* 2015 Nov; 64:1429-35..
209. Rabel A, **Leitman SF**, Miller JL. Ask about ice, then consider iron. *J Am Assoc Nurse Pract*. 2016 Feb; 28:116-20.
210. Panch SR, Yau YY, Fitzhugh CD, Hsieh MM, Tisdale JT, **Leitman SF**. Blood stem cell mobilization is more robust in African American than Caucasian donors and is not affected by sickle cell trait. *Transfusion* 2016 May; 56:1058-65.
211. Vo PT, Pantin J, Ramos C, Cook L, Cho E, Kurlander R, Khuu H, Barrett AJ, **Leitman SF**, Childs RW. Conditioning with rabbit versus horse ATG dramatically alters clinical outcomes in Identical twins with severe aplastic anemia transplanted with the same allogeneic donor. *J Hematol Oncol* 2015 Jun 26; 8:78-83.
212. Hickey BW, Lumsden JM, Reyes S, Sedegah M, Hollingdale MR, Freilich DA, Luke TC, Charoenvit Y, Goh LM, Berzins MP, Bebris L, Sacci JB, De La Vega P, Wang R, Harini D, Ganeshan HD, Abot EM, Carucci DL, Doolan DL, Brice GT, Kumar A, Aguiar J, Nutman TB, **Leitman SF**, Hoffman SL, Epstein JE, Richie, TL. Mosquito bite immunization with radiation-attenuated *Plasmodium falciparum* sporozoites: safety, tolerability, protective efficacy and humoral immunogenicity. *Malar J*. 2016 Jul 22; 15:377-85.
213. Ward DC, Beaulieu GP, **Leitman SF**, Flegel WA. Transfusion medicine illustrated: Transfused neutrophils home to a joint with a fungal infection. *Transfusion* 2016 Nov; 56 (11):2655-2656.

CHAPTERS

1. **Leitman SF:** Posttransfusion graft-versus-host disease. In: Smith DM and Silvergleid AJ (eds). Special considerations in transfusing the immunocompromised patient. American Association of Blood Banks, Arlington, VA p. 15-37, 1985.
2. Klein HG, Balow JE, Dau PC, Hamburger MI, **Leitman SF**, Pineda AA, Tindall RS: Clinical applications of therapeutic apheresis: report of the Clinical Applications Committee, American Society for Apheresis. *J Clin Apheresis* 3:15-16, 21-22, 39-40, 43-44, 1986.
3. **Leitman SF.** Graft-versus-host disease and the role of blood product irradiation. In: Smit Sibinga CT, Das PC, Engelfriet CP (eds). Proceedings, 11th Annual Symposium on Blood Transfusion: White cells and platelets in blood transfusion. Martinus Nijhoff, Boston, MA p.115-129, 1987.
4. **Leitman SF:** The role of apheresis in the adoptive immunotherapy of cancer. In: Kasprisin DO, Westphal RG, eds. Current status of hemapheresis: Indications, technology, and complications. American Association of Blood Banks, Arlington, VA p.105-124, 1987.
5. **Leitman SF:** Immunotherapy of cancer with lymphokine-activated killer cells: The role of transfusion medicine. In: Menitove JE, ed. Hematology 1987: Education Program of the American Society of Hematology. Grune & Stratton, New York, NY p. 39 -44, 1987.
6. **Leitman SF:** Leukocyte inactivation by blood irradiation. In: Rossi EC, Simon TL, Moss GS, Gould SA, eds. Principles of Transfusion Medicine. Williams and Wilkins, Baltimore, MD, 1995.
7. **Leitman SF**, Bolan CD: Hemochromatosis. In: Rodgers GP, Young NS, eds. Bethesda Handbook of Hematology. Lippincott Williams & Wilkins, Baltimore, MD. p. 361-372, 2004.
8. Nambiar A, **Leitman SF:** Transfusion therapy. In: Boyiadzis MC, Lebowitz PF, Frame JN, Fojo T, eds. Hematology-Oncology therapy. McGraw-Hill, New York, NY. p. 607-630, 2006.
9. **Leitman SF**, Bolan CD: Hereditary hemochromatosis. In: Rodgers GP, Young NS, eds. Bethesda Handbook of Hematology. Lippincott Williams & Wilkins, Baltimore, MD. July 2009.
10. **Leitman SF**, Bolan CD: Hereditary hemochromatosis. In: Rodgers GP, Young NS, eds. Bethesda Handbook of Hematology. Lippincott Williams & Wilkins, Baltimore, MD. Dec 2012.
11. **Leitman SF.** Hemochromatosis: the new blood donor. *Hematology Am Soc Hematol Educ Program.* 2013;2013:645-50.

ABSTRACTS

1. Bennett JS, Hoxie JA, **Leitman SF**, Vilaire G, Cines DB: Inhibition of fibrinogen binding to human platelets by a monoclonal antibody. *Blood* 60:194a, 1982.
2. **Leitman SF**, Jenkins TC, Greene RF, Davey RJ: Compatibility of intravenous morphine sulfate with red blood cell transfusions. Mid-Atlantic Association of Blood Banks, 1984.
3. **Leitman SF**, Lee BJ, McGinniss MH, Shulman NR, Frank MM: Massive immune hemolysis, disseminated intravascular coagulation and acute renal failure in association with tolmetin ingestion. *Transfusion* 24:426, 1984.
4. Meyer MT, **Leitman SF**, Smith HR: Serologic abnormalities accompanying angioimmunoblastic lymphadenopathy: an analysis of four cases. Mid-Atlantic Association of Blood Banks, 8th Annual Meeting, 1985.
5. Carter CS, **Leitman SF**, Cullis H, Muul LM, Burchenal KN, Rosenberg SA, Klein HG: Use of a continuous-flow cell separator in density gradient isolation of lymphocytes. *Transfusion* 26:563, 1986.
6. Kodis C, Read EJ, Carter CS, **Leitman SF**: Effect of pre-storage irradiation on posttransfusion platelet survival. *Transfusion* 26:568, 1986.
7. **Leitman SF**, Gregg RE, Adde MA, Smith JW: Selective removal of low density lipoprotein cholesterol by secondary membrane filtration. *Transfusion* 26:579, 1986.
8. **Leitman SF**, Boltansky H, Alter HJ, Pearson FC, Kaliner MA: Allergic reactions in healthy plateletpheresis donors caused by sensitization to ethylene oxide gas. *Transfusion* 26:580, 1986.
9. Kirshenbaum AS, **Leitman SF**, Kaliner MA, Metcalfe D. Intermediate range molecular weight protein responsible for blood product anaphylaxis. *Allergy Clin Immunol* 79:197, 1987.
10. Carter CS, **Leitman SF**, Muul LM, Cullis HM, Rosenberg SA, Klein HG. Semi-automated lymphokine-activated killer (LAK) cell generation using cell separator techniques. *Transfusion* 27:536, 1987.
11. **Leitman SF**, Carter CS, Aebersold P, Rosenberg SA. Simplified generation of lymphokine-activated killer (LAK) cells using apheresis techniques: omission of FicollHypaque sedimentation. *Blood* 70:137a, 1987.
12. **Leitman SF**, Alter HJ, Melpolder JJ, Read EJ, Klein HG. HIV seropositivity in asymptomatic blood donors: A prospective controlled study. *Blood* 70:332a, 1987.
13. Loiacono B, Carter G, **Leitman SF**, Klein HG: Efficacy of various methods of confidential unit exclusion in identifying potentially infectious blood products. *Transfusion* 28:54S, 1988.
14. DePalma L, Carter CS, **Leitman SF**: Granulocyte transfusion therapy in a child with multiple red cell alloantibodies. *Transfusion* 28:18S, 1988.

15. **Leitman SF**: Allergic reactions in healthy granulocytapheresis donors: is sensitization due to ethylene oxide gas or hydroxyethyl starch? *Transfusion* 28:25S, 1988.
16. Saint L, **Leitman SF**: Use of a polyester filter for preparation of leukocyte-depleted platelet concentrates. *Blood* 72:284a, 1988.
17. Goetzman HG, Carter CS, Abrahamsen TG, Read EJ, Yu MY, Rubin M, **Leitman SF**: Preparation of peripheral blood monocytes for transfusion. *Transfusion* 29:6S, 1989.
18. Dowling R, Meyer C, Plunkett A, Carter C, Retzke M, Pavel J, **Leitman SF**: Collection of two components, lymphocytes and platelets, from a single CS-3000 apheresis procedure. *Transfusion* 29:6S, 1989.
19. Higgins MJ, **Leitman SF**, Read EJ, Young NS: Diminished response to platelet transfusion in aplastic anemia patients receiving GM-CSF. *Transfusion* 29:36S, 1989.
20. Dowling R, Burnham V, Fujimura-Justice M, Carter GR, **Leitman SF**: A time study for the performance of therapeutic and donor apheresis procedures. *J Clin Apheresis*, 1989.
21. Curiel D, **Leitman SF**, Hubbard R, Stier L, Sellers S, Plunkett A, Crystal RG: Plasma exchange/alpha-1antitrypsin infusion augmentation for treatment of alpha-1-antitrypsin deficiency. *Am Rev Resp Dis*, 1989.
22. **Leitman SF**, McCoy N, Sullivan J, Spiegel D, Yu M, Davey RJ: The effect of pre-storage irradiation on postransfusion red cell survival. Abstracts of the ISBT/AABB Joint Congress, p.195, 1990.
23. DePalma L, Criss V, Sullivan M, **Leitman S**, Williams A, Luban N: Detection of cytomegalovirus antibody in platelet concentrates by fluorescent immunoassay and latex agglutination. Abst of the ISBT/AABB Joint Congress, p.III, 1990.
24. Carter CS, Cullis H, Read EJ, **Leitman SF**, Klein HG: Use of a recirculating plasma technique to increase platelet yields and decrease white cell content during automated platelepheresis. Abstracts of the ISBT/AABB Joint Congress, p.185, 1990.
25. Zunich KM, Easter M, Wilson W, **Leitman SF**, Fauci AS, Lane HC: Bone marrow transplantation and adoptive transfer of peripheral blood lymphocytes from gp160-immunized syngeneic donors combined with zidovudine, interferon alpha, and recombinant CD4-IgG in the treatment of HIV infection. Seventh International Conference on AIDS, June 1991.
26. Carter CS, Culver KW, Sink B, May FF, **Leitman SF**, Anderson WF, Klein HG, Blaese RM: Preparation of adenosine deaminase (ADA)-corrected T-cells for human gene therapy. *Transfusion* 31:59s, 1991.
27. Wong HM, **Leitman SF**: Evaluation of a new polyester filter for preparation of leukocyte-depleted platelet concentrates. *Transfusion* 31:62s, 1991.
28. Pavel JN, Fratantoni PF, Gram RM, Adore ML, Mason G, **Leitman SF**: Comparison of two methods of conveying HIV/AIDS information to donors: written versus audiovisual techniques. *Transfusion* 31:84s, 1991.

29. Loiacono BR, Klein HG, Leitman SF: Monitoring donor recovery following marrow donation for an unrelated recipient. *Transfusion* 31:85s, 1991.
30. Leitman SF, Plunkett AM, Zachary D: Treatment of familial hypercholesterolemia by dextran-sulfate adsorption apheresis. *Transfusion* 31:42S, 1991.
31. Leitman SF, Miller FW, Dowling RF, Plunkett AM, Cronin ME, Hicks JE, Dalakas MC, Fraser DF, Plotz PH: Randomized double-blind trial of plasma exchange, leukapheresis, and sham apheresis in patients with polymyositis/dermatomyositis. *Transfusion* 31:43S, 1991.
32. Leitman SF, Hill EA, Moore RC, Klein HG: Efficacy of erythrocytapheresis in the treatment of sickle cell disease. *Blood* 78:199a, 1991.
33. Leitman SF, Silberstein L, Fairman RM, Lewis DF. Use of a radiation-sensitive film label in the quality control of irradiated blood components. *Transfusion* 32:4S, 1992.
34. Suda BA, Leitman SF, Davey RJ. Irradiation of red cells prior to long term frozen storage. *Transfusion* 32:70S, 1992.
35. Metter KJ, Lopez-Plaza I, Leitman SF. Recruiting the Hispanic marrow donor. *Transfusion* 32:93S, 1992.
36. Carter CS, May FF, Yu MY, Leitman SF, Klein HG, Chang L, Anderson WF, Culver KW, Blaese RM. Preparation of adenosine deaminase corrected T cells for use in gene therapy. *Transfusion* 32:46s, 1992.
37. Leitman SF, Cottler-Fox M, Shaffer A, Johnson J, Horowitz M. Transfusion-associated graft-versus-host disease in a patient with glioblastoma multiforme. *Blood* 80: 224a, 1992.
38. Cottler-Fox M, Sink B, Carter C, Leitman S, Cullis H, Berenson R. Peripheral blood stem cell collection in unstimulated normal volunteers: efficiency of CD34+ cell collection using leukapheresis combined with monoclonal antibody/biotin-avidin column separation. *Blood* 80:520a, 1992.
39. Leitman SF, Rosenberg SA. Unusual hypersensitivity reactions to albumin in patients undergoing plasma exchange conditioning prior to immunotherapy. *Transfusion* 33:4s, 1993.
40. Cottler-Fox M, Sink BS, Yu M, Leitman SF, Dunbar CE. Mobilization and collection of peripheral blood stem cells for autologous transplant in multiple myeloma using intravenous
41. G-CSF and cyclophosphamide. *Blood* 82:265a, 1993.
42. Dunbar CE, O'Shaughnessey JA, Cottler-Fox M, Carter CS, Cowan KH, Leitman SF, Wilson W, Young NS, Nienhuis AW. Autologous transplantation of retrovirally-marked CD34-immunoselected bone marrow and peripheral blood cells in patients with multiple myeloma or breast cancer. *Blood* 82:217a, 1993.
43. Carter CS, Walker R, May F, Cipolone K, Larsen M, Leitman SF, Blaese RM, Metcalf J, Davey R, Mullen CA, Lane HC, Klein HG. Expansion of syngeneic T lymphocytes in twins discordant for HIV infection. *Blood* 82:416a, 1993.

44. Leitman S, Yu M, Lekstrom J, Malech HL, Gallin JI. Controlled trial of recombinant granulocyte colony-stimulating factor (G-CSF) in healthy leukapheresis donors. *Transfusion* 34:5s, 1994.
45. Lee JH, Leitman SF. A controlled study of the efficacy of hetastarch and pentastarch in granulocyte collections by centrifugal leukapheresis. *Transfusion* 34:59s, 1994.
46. Stroncek DF, Leonard K, Gallin JI, Malech HL, Leitman SF. Alloimmunization following granulocyte transfusions. *Transfusion* 34:77s, 1994.
47. O'Shaughnessy JA, Cowan KH, Cottler-Fox M, Carter CS, Doren S, Leitman SF, Wilson W, Moen R, Nienhuis AW, Dunbar CE. Autologous transplantation of retrovirally-marked CD34-positive bone marrow and peripheral blood cells in patients with multiple myeloma or breast cancer. *Proc Am Soc Clin Oncol* 13:296, 1994.
48. Allen AJ, Leonard H, Castellanos FX, Dow SP, Richter D, Neal J, Leitman SF, Swedo SE. Novel treatments of pediatric infection-triggered, autoimmune neuropsychiatric disorders. *AACAP* 1994.
49. Walker RE, Carter CS, Muul L, Natarajan V, Herpin BR, Leitman SF, Klein HG, Mullen CA, Falloon J, Davey RT, Kovacs JA, Polis MA, Masur H, Blaese RM, Lane HC. Adoptive transfer of genetically modified cells in identical twins discordant for HIV-1 infection. 2nd National Conference on Human Retroviruses. *Am Assoc Infect Dis and Am Soc Microbiol*, 168, 1995.
50. Wexler LH, Leitman SF, Carter CS, McClure L, Yu M, Fox MC. Peripheral blood progenitor cell transfusions permit repetitive cycles of myeloablative chemotherapy for pediatric sarcoma patients. *Proc Am Soc Clin Oncol*, 1995.
51. Luban NLC, Fearon T, Leitman SF, Moroff G. Absorption of gamma radiation in simulated blood components using cesium irradiators. *Transfusion* 35:63s, 1995.
52. Leitman SF, Sekhsaria S, Gladden D, Vowells SJ, Fleisher TA, Malech HL. Safety and efficacy of recombinant granulocyte colony stimulating factor (G-CSF) in mobilizing blood stem cells in healthy donors. *Transfusion* 35:66s, 1995.
53. Leitman SF, Yu M, Lekstrom J. Pair-controlled study of granulocyte colony-stimulating factor (G-CSF) plus dexamethasone for granulocytapheresis donors. *Transfusion* 35:53s, 1995.
54. Davey RJ, Stec NM, Lee JL, Leitman SF. The effect of prestorage leukocyte reduction on the irradiation-induced red cell storage lesion. *Transfusion* 35:55s, 1995.
55. Stein D, Mackall C, Bare C, Brown M, Carter C, Casey N, Yu M, Fleisher T, Leitman S, Shearer G, Wexler L, Gress R. Impaired immune reconstitution post sequential high dose chemotherapy and autologous peripheral blood stem cell infusion. *Blood* 86:104a, 1995.
56. Wexler LH, McClure LW, Carter CS, Yu M, Cottler-Fox M, Leitman SF. Use of CD34-selected peripheral blood progenitor cell collections to allow dose intensification in pediatric sarcoma patients. *Blood* 86:232a, 1995.

57. Emmons R, Doren S, Hines K, Carter CS, Cottler-Fox M, O'Shaughnessy J, Leitman SF, Cowan K, Dunbar CE. Comparison of retroviral transduction conditions for gene marking of adult peripheral blood or marrow derived CD34+ cells in a clinical trial. *Blood* 86:238a, 1995.
58. Sekhsaria S, Fleisher TA, Vowells SJ, Brown M, Miller JA, Gordon I, Blaese RM, Leitman SF, Malech HL. Kinetics of G-CSF recruitment of peripheral blood CD34+ cells: normal volunteers and two patient groups with inherited hematopoietic disorders. *Blood* 86:583a, 1995.
59. Malech HL, Sekhsaria S, Whiting-Theobald N, Linton GF, Vowells SJ, Li F, Miller JA, Holland SM, Leitman SF, Carter CS, Read EJ, Fleisher TA, Deans RJ, Spratt SK, Maack CA, Rokovich JA, Cohen LK, Maples PB, Gallin JI. Development of a phase I clinical trial of gene therapy for chronic granulomatous disease. *Blood* 86:295a, 1995.
60. Pavel J, Morgan V, Leitman SF. Design and use of a computer application to search for HLA compatible platelet donors. *Transfusion* 36:88s, 1996.
61. Gladden SD, Kessel O, Pavel J, Leitman SF. Feasibility and safety of using peripherally inserted central catheters (PICC) for red cell transfusions. *Transfusion* 36:46s, 1996.
62. Leitman SF, Oblitas JM, Emmons R, Dunn DE, Young NS. Clinical efficacy of daily G- CSF-recruited granulocyte transfusions in patients with severe-neutropenia and life-threatening infections. *Blood* 88:331a,1996
63. Mavroudis D, Read EJ, Carter CS, Leitman SF, Molldrem J, Emde M, Berninger R, Barrett AJ. T-cell depletion of G-CSF mobilized peripheral blood progenitor cells from normal donors. *Blood* 88:254a, 1996.
64. Malech HL, Sekhsaria S, Whiting-Theobald N, Linton GF, Vowells SJ, Li F, Miller JA, Holland SM, Leitman SF, Carter CS, Read EJ, Fleisher TA, Deans RJ, Spratt SK, Maack CA, Rokovich JA, Cohen LK, Maples PB, Gallin JI. Prolonged detection of oxidase-positive neutrophils in the peripheral blood of five patients following a single cycle of gene therapy for chronic granulomatous disease. *Blood* 88:486a, 1996.
65. Leitman SF, Werden R, Garvey MA, Swedo SE. Randomized trial of plasma exchange, immune globulin or steroids in children with Sydenham's chorea. *Transfusion* 37:68s, 1997.
66. Oblitas JM, Sigmon JM, Leitman SF. Prospective comparison of plateletpheresis yields using the Fenwal Amicus versus the CS-3000 Plus cell separators. *Transfusion* 37:5s, 1997.
67. Smith JD, Leitman SF. Filtration of red cell units: effect of storage time and temperature on filter performance. *Transfusion* 37:14s, 1997.
68. Leitman SF, Oblitas JM. Optimization of granulocytapheresis mobilization regimens using granulocyte colony stimulating factor (G-CSF) and dexamethasone. *Transfusion* 37:67s, 1997.
69. Dunbar CS, Kohn DB, Schiffman R, Barton NW, Nolte J, Wells S, Emmons RVB, Leitman SF, Carter CS, Young NS, Brady RO, Karlsson S. Retroviral gene transfer of the

glucocerebrosidase gene into PB or BM CD34+ cells from patients with Gaucher Disease: results of a clinical trial. *Blood* 90:237a, 1997.

70. Liu JM, Kim S, Read EJ, Carter CS, Leitman SF, Young NS, Walsh CE. Experimental trial of gene therapy for group C Fanconi anemia patients: 2 year follow up. *Bood* 90:239a, 1997.
71. Sink B, Werden R, Garvey M, Swedo SE, Leitman SF. Efficacy of plasma exchange versus immune globulin in the treatment of sydenham's chorea. *J Clin Apheresis*, 1998.
72. Birmingham GC, Carr JM, Martin CL, Leitman SF. Comparison of mononuclear efficiencies with two single needle discontinuous flow apheresis devices. *Transfusion* 38:4S, 1998.
73. Lazarus EF, Browning J, Oblitas JM, Leitman SF. Non-transient decreases in platelet count associated with multiple regular plateletpheresis donations. *Transfusion* 38:98S, 1998.
74. Huhn RD, Read EJ, Rick M, Leitman SF, Gratwohl A, Young NS, Barrett AJ, Dunbar CE. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia. *Blood* 92:178a, 1998.
75. Stroncek D, Leitman SF. Fall in pH accompanies storage of G-CSF-mobilized granulocyte concentrates. *Blood* 92:53a, 1998.
76. Lehrnbecher T, Foster CB, Zhu S, Leitman SF, Huppi K, Chanock S. Analysis of biologically significant variant alleles of the low affinity Fc gamma receptor cluster in a healthy population: a foundation for genetic annotation studies that further defines the recently identified SH-FcGR3b as an independent locus. *Blood* 92:162a, 1998.
77. Zujewski J, Chiao J, Riseberg D, Cusack G, Hakim F, Kohler D, Chow C, Leitman SF, Chen C, Deo Y, Curnow R, Seigel D, Gress R, Cowan KH. A phase I trial of bispecific antibody, MDXH210, in patients with HER2 positive advanced cancer. Medarex, Inc. Annandale, NJ, National Institutes of Health, Bethesda, MD. American Association for Clinical Research 1999.
78. Cowan KH, Short K, Huang H, Zujewski J, Cusack G, Carter CS, Goldspiel B, Leitman SF, Read EJ, Abati A, Sellers S, Gottesman MM, Pastan I, Dunbar C, Moscow JA. Effects of chemotherapy on breast cancer patients engrafted with peripheral blood progenitor cells transduced with retroviral vectors expressing MDR1 or NeoR gene. ASCO, 1999.
79. Bolan CD, Zujewski J, Mansky P, Gladden SD, Kohn EC, Leitman SF. Plasma exchange in gemcitabine-associated thrombotic microangiopathy. *J Clin Apheresis*, 1999.
80. Bolan CD, Arioglu E, Sumner AE, Birmingham GC, Taylor SI, Leitman SF. Intensive plasma exchange for severe hypertriglyceridemia in acquired total lipotrophy. *J Clin Apheresis*, 1999.
81. Wong E, Oblitas J, Stroncek D, Leitman SF. Whole blood platelet von Willebrand bead reactivity in plateletpheresis donors: effect of age, gender and medications. *Transfusion* 39:38S, 1999.

82. Wong E, Oblitas J, Rivera C, Leitman SF, Stroncek D. Von Willebrand factor (VWF) coated bead reactivity and flow cytometric markers of platelet activation in pheresis platelets. *Transfusion* 39:89S, 1999.
83. Stroncek D, Procter J, Moses L, Bolan CD, Pomper G, Cantelina CC, Leitman SF. Rh immune globulin prevents RH(D) alloimmunization in granulocyte recipients, but obscures detection of alloanti-K1. *Transfusion* 39:61S, 1999.
84. Pomper GJ, Carter CS, Leitman SF, Read EJ. Cellular composition of normal donor leukapheresis products before and after G-CSF mobilization. *Transfusion* 39:79S, 1999.
85. Pomper GJ, Rick ME, Epstein JS, Read EJ, Leitman SF. Management of severe von Willebrand's disease with cryoprecipitate collected by repeated apheresis of a single dedicated donor. *Transfusion* 39:112S, 1999.
86. Bolan CD, Childs R, Procter JL, Barrett AJ, Leitman SF. Severe immune hemolysis due to minor ABO incompatibility after peripheral blood stem cell (PBSC) transplantation. *Transfusion* 39:85S, 1999.
87. Bolan CD, Rehak N, Remaley A, Horne M, Pomper GF, Birmingham GC, Gladden SD, Leitman SF. Clinical and laboratory evaluation of citrate effects and calcium replacement therapy in large volume leukapheresis (LVL). *Transfusion* 39:122S, 1999.
88. Leitman SF, Werden RA, Garvey MA, Feldman E, Swedo SE. Randomized trial of plasma exchange vs immune globulin in childhood-onset obsessive compulsive disorder (OCD). *Transfusion* 39:112S, 1999.
89. Saif MW, Freifeld A, horne M, Leitman SF, Cusack G, Cowan KH, Zujewski J. Pulmonary embolism following removal of apheresis catheters in patients with malignancy. *Blood* 94:341b, 1999.
90. Nakamura R, Huhn RD, Read EJ, Rick M, Leitman SF, Gratwohl A, Young NS, Barrett AJ, Dunbar CE. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia. *Blood* 94:646a, 1999.
91. Choi E, Lehrnbecher, Zhu S, Foster CB, Heller S, Goldin L, Leitman SF, Chanock SJ. Distribution of variant genotypes of the NADPH-oxidase components, p22-phox and p67-phox in two healthy populations. *Blood* 94:210a, 1999.
92. Horwitz ME, Barrett AJ, Childs R, Miller JA, Leitman SF, Read EJ, Carter CS, Malech HL. Nonmyeloablative, T-cell depleted allogeneic peripheral blood stem cell (PBSC) transplantation for patients with chronic granulomatous disease. *Blood* 94:710a, 1999.
93. Bolan CD, Cantelina CC, Mason G, Leitman SF. Value of the mean corpuscular volume as a guide to phlebotomy therapy in genetic hemochromatosis. *Blood* 94:590a, 1999.
94. Bahceci E, Read EJ, Leitman SF, Carter CS, Childs R, Dunbar C, Young NS, Barrett AJ. Treatment of chronic myelogenous leukemia with T-cell depleted hematopoietic stem cell

- transplantation followed by delayed T cell add-back. *Blood* 94:166a, 1999.
95. Childs R, Contentin N, Clave E, Bahceci E, Hensel N, Boland CD, Pomper EJ, Read EJ, Leitman SF, Dunbar C, Young NS, Barrett AJ. Reduced toxicity and transplant related mortality following nonmyeloablative allogeneic peripheral blood stem cell transplantation for malignant diseases. *Blood* 94:393a, 1999.
 96. Wong E, Oblitas J, Tisdale JF, Walsh T, Young NS, Leitman SF. Efficacy of G-CSF/ dexamethasone-mobilized granulocyte transfusions in the treatment of life-threatening infections in patients with severe aplastic anemia (SAA). *Blood* 94:126a, 1999.
 97. Leitman SF, Illei GG, Tisdale J, Foley A, Popovsky MA, Balow JE, Boumpas DT. Fludarabine therapy as an independent risk factor for transfusion-associated graft-versus-host disease (TA-GVHD). *Transfusion* 40:126s, 2000.
 98. Leitman SF, Kirk AD, Gladden DS, Kopp J. Plasma exchange in the treatment of recurrent focal segmental glomerulosclerosis (FSGS) following renal transplant. *Transfusion* 40: 54s, 2000.
 99. Bolan CD, Cecco S, Oblitas J, Greer S, Remaley A, Wesley R, Rehak N, Leitman SF. Double-blind, placebo-controlled study of prophylactic oral calcium carbonate administration in plateletpheresis donors. *Transfusion* 40:22s, 2000.
 100. Harvath L, Mondoro TH, Franke PJ, Aksamit RR, Lightfoot T, Leitman SF, Stroncek DF. Granulocyte concentrates: chemotactic activity and platelet-granulocyte interactions are differentially affected by mobilization regimen and storage. *Transfusion* 40:12s, 2000.
 101. Kang EM, Areman E, Read EJ, Link B, Leitman SF, Rodgers GP, Tisdale JF. Safety and feasibility of stem cell mobilization and large-volume apheresis in donors with sickle cell trait. *Blood* 2000.
 102. Bolan CD, Childs R, Griffith L, Procter J, Stroncek D, Barrett AJ, Leitman SF. Pure red cell aplasia and delayed erythroid engraftment in non-myeloablative PBSC transplantation with major ABO incompatibility. *Blood* 2000.
 103. Taylor JG, Tang D, Leitman SF, Heller S, Serjeant GR, Rodgers GP, Chanock SJ. Identification of single nucleotide polymorphisms (SNPs) in cell adhesion molecules for a pilot study in stroke and sickle cell disease. *Blood* 2000.
 104. Stroncek DF, Yau YY, Leitman SF. G-CSF plus dexamethasone administration produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. *Blood* 2000.
 105. Browning J, Sparks E, Gladden SD, Fratantoni P, Leitman SF. Computer-based analysis of scheduling challenges in a therapeutic apheresis clinic. ASFA Annual Meeting, May 2001
 106. Moncada V, Yau YY, Gladden SD, Browning J, Leitman SF. Determination of a threshold CD34 cell count for performance of PBSC collection in donors with a poor mobilization response to filgrastim. ASFA Annual Meeting, May 2001.

107. Leitman SF, Browning J, Mason G, Yau YY, Conry-Cantilena C, Bolan CD. Operational impact of using hemochromatosis subjects as allogeneic whole blood donors. *Transfusion*, 2001.
108. Bolan CD, Yau YY, Mason G, Browning J, Conry-Cantilena C, Leitman SF. MCV-guided phlebotomy therapy for hemochromatosis (HH). *Transfusion*, 2001.
109. Leitman SF, Oblitas JM, Bolan CD. Crescendo angina during granulocytapheresis in a G-CSF stimulated donor. *Transfusion*, 2001.
110. Bolan CD, Yau YY, Wesley R, Cecco SA, Rehak NR, Leitman SF. Influence of gender on citrate-related effects during large volume leukapheresis. *Transfusion*, 2001.
111. Stroncek DF, Matthews C, Leitman, SF. Same-day mobilization and collection of granulocytes. *Transfusion*, 2001.
112. Bishop MR, Marchigiani D, Castro K, Kasten-Sportes C, Carter CS, Read EJ, Leitman SF, Gress R, Fowler D. Pre-transplant quantitation of host T-cells as a method to determine adequate immune suppression for successful engraftment of T-cell depleted allografts after reduced-intensity conditioning. *Blood* 2001;**98**:189a.
113. Solomon SR, Nakamura R, Read EJ, Leitman SF, Childs RW, Dunbar CE, Young NS, Barrett AJ. Is cyclosporine necessary to prevent graft versus host disease after T cell depleted peripheral blood stem cell transplantation? *Blood* 2001;**98**:416a.
114. Fogarty P, Huhn RD, Nakamura R, Read EJ, Rick ME, Leitman SF, Greene A, Gratwohl A, Young NS, Barrett AJ, Dunbar CE. Intensive immunosuppression with high-dose cyclophosphamide and autologous CD34+ selected hematopoietic cell support for chronic refractory autoimmune thrombocytopenia (AITP): a follow-up report. *Blood* 2001;**98**:442a.
115. Anasetti C, Haagenson M, Kollman C, Matlack M, Anderlini P, Fisher J, Rowley SD, Leitman SF, Stroncek D, Wingard JR, Confer D. Transplantation of G-CSF-mobilized blood stem cells from unrelated donors. *Blood* 2001;**98**:858a.
116. Confer D, Haagenson M, Anderlini P, Fisher J, Leitman S, Kollman C, Rowley SD, Stroncek D, Wingard JR, Anasetti C. Collection of rhG-CSF-mobilized blood stem cells from 395 unrelated donors. *Blood* 2001;**98**:857a.
117. Ramirez CM, Yau YY, Mason G, Browning J, Cantilena CC, Leitman SF, Bolan CD. Effect of iron burden and carefully controlled phlebotomy therapy on arthritic symptoms in hereditary hemochromatosis. *Blood* 2001;**98**:7a.
118. Bolan CD, Yau YY, Mason G, Browning J, Cantilena CC, Leitman SF. Changes in iron parameters during MCV-guided phlebotomy therapy for hereditary hemochromatosis. *Blood* 2001;**98**:62a.
119. Bolan CD, Cecco SA, Wesley Ra, Yau YY, Horne M, Remaley AT, Childs RW, Barrett AJ, Rehak NN, Leitman SF. Controlled study of donor symptoms, citrate effects, and response to intravenous calcium in large volume leukapheresis. *Blood* 2001;**98**:63a.

120. Leitman SF, Victoria Sharon, Noguchi CT, Schechter AN, Klein HG, Stroncek DF. Collection of sickle cell trait red cells by apheresis allows effective leukocyte reduction by filtration. *Blood* 2001;**98**:829a.
121. Stroncek DF, Rainer T, Cipolone KM, Noguchi CT, Klein HG, Schechter AN, Leitman SF. Hemoglobin S polymerization in sickle cell trait RBCs prevents effective leukocyte reduction by filtration. *Blood* 2001;**98**:828a.
122. Greer SE, Leitman SF, Shih JWK, Conry-Cantilena C, Melpolder JJ, Schechterly C, Ness PM, Gible JW, Alter HJ. A 17-year prospective evaluation of HIV outcomes in a cohort enrolled as asymptomatic blood donors. *Transfusion* 2002;**42**:23S.
123. Byrne KM, Stroncek DF, Leitman SF. Increasing oxygen tension prevents the occlusion of leukocyte reduction filters in sickle cell trait donor RBCs. *Transfusion* 2002;**42**:15S.
124. Bolan CD, Yau YY, Carter CS, Cullis H, Leitman SF. Effect of device settings and whole blood flow rate (WBFR) on PBSC collection efficiency. *Transfusion* 2002;**42**:31S.
125. Leitman SF, Oblitas J, Sparks E, Browning JN. Commitment to blood donation by disaster appeal respondents. *Transfusion* 2002;**42**:123S.
126. Lockwood FL, Csako G, Choyke P, Cannon R, Wesley R, Ruiz M, Giesel F, Fu X, Costello R, Leser M, Schenke W, Sink B, Pucino F, Leitman SF. Frequent blood donation fails to improve markers of atherosclerosis. *Transfusion* 2002;**42**:65S.
127. Browning JN, Sink BS, Leitman SF. Simplifying the eligibility evaluation of donors who travel to foreign countries. *Transfusion* 2002;**42**:118S.
128. Leitman SF, Browning JN, Yau YY, Mason G, Klein HG, Cantilena CC, Bolan CD. Impact of using hemochromatosis subjects as allogeneic blood donors. *Blood* 2002.
129. Fowler DH, Hou J, Fellowes V, Vance B, Bishop MR, Gress RE, Levine B, June CH, Leitman SF, Read EJ, Carter CS. Donor Th2 cells for GVHD modulation: clinical scale and grade generation using CD3, CD28 costimulation. *Blood* 2002.
130. Stroncek D, Byrne K, Leitman SF. Storage of sickle trait donor blood in oxygen permeable bags with a large surface area allows effective leukoreduction by filtration. *Transfusion* 2003;**43**:42a.
131. Kolf C, Bolan CD, Wesley R, Browning JN, Leitman SF. Sustained decreases in lymphocyte counts in serial long-term leukapheresis donors. *Transfusion* 2003;**43**:28a.
132. Bolan CD, Yau YY, Nambiar A, Haddad S, Leitman SF. Inadvertent hypercalcemia during intravenous calcium prophylaxis for large volume leukapheresis. *Transfusion* 2003;**43**:28a.
133. Stroncek DF, Shawker T, Dittmar K, Heatherman A, Leitman SF. G-CSF-Induced splenic enlargement in peripheral blood hematopoietic progenitor cell donors resolves within 10 days. *Blood* 2003;**102**:957a.

134. Reese A, Stevens WT, Donohue T, Chakrabarti S, Wesley R, Castro K, Fowler DH, Bishop MR, Leitman SF, Childs RW, Bolan CD. Clinical and laboratory features of minor ABO incompatible reduced intensity blood hematopoietic cell transplantation using cyclosporin (CsA) vs CsA/mycophenolate mofetil for graft-vs-host disease prophylaxis. *Blood* 2003;102:708a.
135. Chakrabarti S, Takahashi Y, Srinivasan R, Marquesen M, Shalabi RA, Goodwin R, Swanson P, Bolan CD, Leitman SF, Barrett AJ, Young NS, Childs R. Durable engraftment and long-term survival following fludarabine-based nonmyeloablative hematopoietic cell transplantation in allo-immunized patients with ATG-refractory severe aplastic anemia and paroxysmal nocturnal hemoglobinuria. *Blood* 2003;102:469a.
136. Confer DL, Leitman SF, Papadopoulos EB, Price TH, Stroncek DF, Robinett P, Braem B. Serious complications following unrelated donor marrow collection: experiences of the National Marrow Donor Program. *Blood* 2003;102:490a.
137. Haddad SA, Leitman SF, Wesley RA, Cecco SA, Yau YY, Starling J, Rehak NN, Bolan CD. Randomized placebo-controlled study of intravenous magnesium supplementation during large volume leukapheresis in healthy allogeneic donors. *J Clin Apheresis* 2004;19:44.
138. Stevens WT, Bolan CD, Oblitas JM, Bennett JE, Leitman SF. *Streptococcus agalactiae* sepsis following transfusion of a plateletpheresis concentrate: relevance of donor evaluation. *J Clin Apheresis* 2004;19:20-21.
139. Pittman PR, Barrera JG, Leitman SF, Marano NN, Norris SL, Ranadive MV, McKee KT. Protective antigen (PA) and toxin neutralization (TNA) antibody patterns in anthrax vaccinees undergoing serial plasmapheresis. IDSA Annual Meeting, Sep 2004.
140. Shizukuda Y, Bolan CD, Tripodi D, Yau YY, Smith K, Nguyen T, Sachdev V, Finkel T, Leitman SF, Rosing DR. Characterization of exercise-induced electrocardiographic changes in hereditary hemochromatosis patients who are New York Heart Association functional class I: role of oxidant stress. Am Heart Assoc Annual Meeting, Fall 2004.
141. Shizukuda Y, Nguyen T, Bolan CD, Sachdev V, Tripodi D, Inez E, Yau YY, Leitman SF, Finkel T, Rosing D. Role of oxidative stress in peak early relaxation tissue Doppler velocities in patients with hereditary hemochromatosis. Am Heart Assoc Annual Meeting, Fall 2004.
142. Hill JM, Powell TM, Paul JD, Zalos G, Syed MA, Arai AE, Read EJ, Khuu HM, Leitman SF, Horne M, Csako G, Dunbar CE, Cannon RO. Efficacy and risk of granulocyte colony-stimulating factor in patients with coronary artery disease and chronic ischemia. Am Heart Assoc Annual Meeting, Fall 2004.
143. Tudisco C, Jett BW, Atkins JW, Byrne KC, Oblitas JM, Leitman SF, Stroncek DF. Ph as a quality control indicator for apheresis platelets. *Transfusion* 2004; 44:178a.
144. Patel HD, Byrne KC, Horne M, Leitman SF, Stroncek DF. Factors affecting the formation of white particulate matter. *Transfusion* 2004; 44:72a.

145. Montero A, Kurlander R, Read EJ, Leitman SF, Nlonda N, Young N, Childs R, Solomon S, Barrett J. Favorable impact of T cell depleted PBSCT on transplant outcomes despite delayed donor T cell engraftment. *Blood* 2004;104:56a.
146. Chakrabarti S, Takahashi Y, Srinivasan R, Espinoza I, Igarashi T, Suffredini A, Marquesen M, Shalabi RA, Bolan CD, Leitman SF, Barrett AJ, Young NS, Childs R. Durable engraftment and long term survival following fludarabine-based nonmyeloablative hematopoietic cell transplantation in patients with ATG-refractory severe aplastic anemia and other nonmalignant hematologic disorders. *Blood* 2004;104:75a.
147. Takahashi Y, Chakrabarti S, Srinivasan R, Lundqvist A, Read EJ, Khuu H, Leitman SF, Bolan CD, Barrett AJ, Calandra G, Childs R. A detailed phenotypic analysis of using six color flow cytometry of lymphocyte subsets mobilized with AMD3100 compared to G-CSF. *Blood* 2004;104:120a.
148. Srinivasan R, Geller N, Chakrabarti S, Espinoza I, Donohue T, Leitman SF, Bolan CD, Read EJ, AJ Barrett, Childs R. Evaluation of three different cyclosporine-based graft versus host disease prophylaxis regimens following nonmyeloablative hematopoietic stem cell transplantation. *Blood* 2004;104:349a.
149. Bolan CD, Yau YY, Kim C, Celi FS, Leitman SF. Prevalence and clinical impact of abnormal thyroid function tests in hereditary hemochromatosis. *Blood* 2004;104:744a.
150. Chakrabarti S, Takahashi Y, Read EJ, Khuu H, Goodwin R, Leitman SF, Bolan CD, Srinivasan R, AJ Barrett, Calandra G, Childs R. A comparison of apheresis cell content collected from the same donors mobilized with G-CSF vs a single injection of AMD3100. *Blood* 2004;104:780a.
151. Savani B, Kurlander R, Read EJ, Leitman SF, Nlonda N, Young N, Childs R, Solomon S, Barrett J. The post-transplant day 30 lymphocyte count strongly correlates with transplanted CD34 dose and is predictive for minimal residual disease and mortality in patients with CML undergoing allogeneic stem cell transplants from matched siblings. *Blood* 2004;104:911a.
152. Shizukuda Y, Bolan CD, Tripodi DJ, Sachdev V, Nguyen T, Inez E, Yau YY, Leitman SF, Rosing DR. Altered diastolic function in asymptomatic patients who were newly diagnosed with hereditary hemochromatosis: utilization of strain rate imaging. *J Am Coll Cardiol* 2005;45:255a.
153. Shizukuda Y, Bolan CD, Tripodi DJ, Sachdev V, Nguyen T, Inez E, Yau YY, Finkel T, Leitman SF, Rosing DR. Role of oxidative stress in diastolic function in patients with hereditary hemochromatosis. *J Am Coll Cardiol* 2005;45:129a.
154. Shizukuda Y, Bolan CD, Nguyen T, Tripodi DJ, Smith KP, Sachdev V, Birdsall CW, Yau YY, Leitman SF, Rosing DR. Preserved left ventricular systolic function during exercise in asymptomatic patients with iron overload secondary to hereditary hemochromatosis. *FASEB J* 2005;19:584a.

155. Nguyen T, Shizukuda Y, Bolan C D, Nguyen T, Tripodi DJ, Smith KP, Sachdev V, Yau YY, Leitman SF, Finkel T, Rosing DR. Correlation between reactive oxygen species and iron levels in NYHA Class I hereditary hemochromatosis patients. *FASEB J* 2005;19:670a.
156. Ronquillo JG, Alvandi F, Reynolds JC, Cecco SA, Wesley RA, Yau YY, Oblitas JM, Collins MT, Rehak NN, Leitman SF, Bolan CD. Citrate effects and bone mineral density (BMD) in serial long-term apheresis donors. *Transfusion* 2005; 45:15a.
157. Stevens WT, Childs RW, Leitman SF, Stroncek DF, Bolan CD. Passenger lymphocyte associated hemolysis in an Rh-D positive patient after peripheral blood stem cell (PBSC) transplantation from an Rh-D negative sibling donor. *Transfusion* 2005; 45:4a.
158. Provenzano M, Selleri S, Ping J, Wang E, Adams S, Panelli M, Leitman SF, Stroncek DF, Marincola F. Comprehensive epitope mapping of the Epstein-Barr Virus Latent Membrane Protein-2 in ethnically diverse populations. International Society for Biological Therapy of Cancer. Alexandria, VA. November 2005.
159. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Nugyen TT, Gilerto B, Sidenko S, Sachdev V, Ernst I, Waclawiw MA, Leitman SF, Rosing DR. Left atrial contractile function is augmented in asymptomatic subjects with hereditary hemochromatosis. *Am J Cardiol* 2005.
160. Shizukuda Y, Bolan CD, Tripodi DJ, Yau YY, Nugyen TT, Smith KP, Waclawiw MA, Leitman SF, Rosing DR. Exercise performance in asymptomatic subjects with hereditary hemochromatosis: abnormal electrocardiographic changes and complex arrhythmias. *Am J Cardiol* 2005.
161. Stevens W, Yau YY, Byrne P, Dunning T, Cecco S, Rehak N, Leitman SF, Bolan CD. Double-blind, placebo-controlled trial of intravenous calcium prophylaxis in plateletpheresis: effect on donor symptoms, product quality, and recipient count increment. *J Clin Apheresis* 2006; 21:2-3.
162. Bolan C, Yau YY, Carter CS, Rehak N, Gladden SD, Klein HG, Read EJ, Leitman SF. Optimization of peripheral blood progenitor cell collection by large volume leukapheresis: a 10 year history of continuous quality improvement. *Transfusion* Oct 2006; 46:30a.
163. Bryant B, Cantilena C, Ahlgren A, Stroncek DF, Gible J, Leitman SF. *Pasteurella multocida* bacteremia in asymptomatic plateletpheresis donors. *Transfusion* Oct 2006; 46:50a.
164. Muniz M, Fadeyi E, Cecco S, Gladden S, Malech H, Pavletic S, Rehak N, Leitman S, Bolan CD. Symptomatic hypercalcemia due to intravenous Ca prophylaxis during LVL in patients with mild renal dysfunction: prevention and management. *Transfusion* Oct 2006; 46:49a.
165. Balow J, Nikolov N, Illei G, Yarboro C, Leitman SF, Grammer A, Austin H, Lipsky P, Gress R, Pavletic S. Autologous stem cell transplantation in systemic lupus erythematosus (SLE): effective immune depletion following a novel lymphoablative regimen. American Society of Nephrology, November 2006.
166. Nikolov NP, Illei GG, Yarboro C, Hakim F, Leitman SF, Read EJ, Khuu H, Grammer A, Fischer R, Balow J, Austin H, Gea-Banacloche J, Muraro P, Babb R, Krumlauf M, Sportes C, Lipsky P, Gress R, Pavletic S. Effective immune depletion following novel lymphoablative regimen for autologous hematopoietic stem cell transplantation in systemic

- lupus erythematosus. Am Coll Rheum Annual Scientific Meeting, Washington DC, Nov, 2006.
167. Arena R, Shizukuda Y, Bolan CD, Tripodi D, Yau YY, Smith K, Waclawiw M, Leitman SF, Rosing D. Relationship between transferrin and ventilatory economy during exercise in asymptomatic hereditary hemochromatosis subjects: Am College Sports Medicine, Annual Meeting, June, 2007.
 168. Daniel-Johnson JA, Yau YY, Bryant BJ, Gladden D, Leitman SF, Bolan CD. Fingerstick hemoglobin varies markedly with changes in body position: comparison to venous hemoglobin. Transfusion 2007 Sep Suppl 47:12a.
 169. Ronquillo JG, Yau YY, Stevens WT, Cecco SA, Alvandi F, Byrne P, Matthews C, Collins M, Wesley RA, Rehak N, Leitman SF, Bolan CD. Acute and sub-acute citrate mediated effects and responses to intravenous calcium in healthy apheresis donors. Transfusion 2007 Sep Suppl 47:14a.
 170. Bryant BJ, Khuu HM, Uzel G, Holland SM, Leitman SF. Topical granulocyte concentrates for chronic wound healing in a patient with leukocyte adhesion deficiency-1. Transfusion 2007 Sep Suppl 47:16a.
 171. Bryant BJ, Hopkins JA, Leitman SF. Evaluation of low red cell mean corpuscular volume in an apheresis donor population. Transfusion 2007 Sep Suppl 47:44a.
 172. Bryant BJ, Leitman SF. Gravity sedimentation of granulocytapheresis concentrates with hydroxyethylstarch efficiently removes red cells and retains neutrophils. Transfusion 2007 Sep Suppl 47:82a.
 173. Patel AJ, Bryant BJ, Wesley RA, Bolan CD, Leitman SF. Capillary versus venous hemoglobin determination in the eligibility assessment of healthy blood donors. Transfusion 2007 Sep Suppl 47:115a.
 174. Bryant BJ, Yau YY, Arceo SM, Hopkins J, Daniel-Johnson J, Bolan CD, Leitman SF. Iron replacement therapy in the routine management of blood donors. Transfusion Sep 2008;48:39a.
 175. Bryant BJ, Yau YY, Arceo SM, Hopkins J, Leitman SF. Ascertainment of iron deficiency and depletion in donors through screening questions for pica and restless legs syndrome. Transfusion Sep 2008;48:40a.
 176. Yau YY, Leitman SF, Daniel-Johnson J, Gladden D, Bryant BJ, Bolan CD. Pre-donation fingerstick and hemoglobin levels vary significantly according to body position, but accurately predict an adequate red cell unit hemoglobin content regardless of position. Transfusion Sep 2008;48:67a.
 177. Daniel-Johnson J, Lee-Stroka A, Schechterly C, Pantin J, Scheinberg P, Alter HJ, Leitman SF, Quillen K. Probiotic-associated high-titer anti-B in a group A platelet donor as a cause of severe hemolytic transfusion reactions. Transfusion Sep 2008;48:260a.

178. Tanno T, Noh SJ, Byrnes C, Bhupatiraju A, Meier ER, Rabel A, Lee YT, Leitman SF, Miller JL. Iron depleted erythropoiesis: slow but effective. *Blood* 2008.
179. Wehbe RM, Yau YY, Wesley RA, Bolan CD, Leitman SF. Risk of total joint arthroplasty in patients with C282Y-homozygous hemochromatosis. *Transfusion* 2009;49:14A.
180. Leitman SF, Yau YY, Belak M, Matthews C, Min AK. Unstimulated mononuclear cell apheresis collections in healthy donors: comparison of two continuous-flow devices. *Transfusion* 2009;49:77A.
181. Illei GG, Nikolov NP, Hasni SA, Hakim F, Leitman SF, Yarboro C, Balow J, Austin H, Gea-Banacloche J, Lipsky P, Gress R, Pavletic S. Long-term outcome of autologous hematopoietic stem cell transplantation using lymphoablative conditioning in recalcitrant systemic lupus erythematosus patients. Ninth International Congress on Systemic Lupus Erythematosus, Vancouver, BC. *Arthritis Research*. Jun 2010.
182. Leitman SF, Vitale SE, Kim J, Byrne PJ, Conry-Cantilena C, Clayton JA. Risk of posterior subcapsular cataracts in granulocyte and platelet apheresis donors. *Transfusion* 2010;50:14A.
183. Leitman SF, Yau YY, Matthews CL, Hopkins JA, Min K. Optimization of unstimulated mononuclear cell collections using the Amicus continuous-flow apheresis device. *Transfusion* 2010;50:15A.
184. Fowler CJ, Yau YY, Bolan CD, Leitman SF. Analysis of donor demographic and laboratory parameters affecting CD34⁺ cell mobilization in healthy allogeneic pediatric peripheral blood stem cell (PBSC) donors. *Blood* 2010;116: A.
185. Borge D, Narda T, Malech HL, Leitman SF, Kang E. Successful control of preexistent active infection by granulocyte transfusions during conditioning induced cytopenia in patients with chronic granulomatous disease undergoing hematopoietic stem cell transplant. *Blood* 2010.
186. Switzer GE, Harrington D, Haagenson M, Drexler R, Foley A, Confer D, Bishop M, Anderlini P, Rowley S, Leitman SF, Anasetti C, Wingard J. Health-Related quality-of-life among adult unrelated stem cell donors: A Blood and Marrow Transplant Clinical Trials Network randomized trial of marrow versus PBSC donation. *Blood* 2010.
187. Uchida N, Bonifacino A, Krouse AE, Fasano RM, Csako G, Leitman SF, Metzger ME, Hsieh MM, Mattapallil JJ, Tisdale JF, Donahue RE. Long-term reconstitution of transduced rhesus CD34⁺ cells mobilized by G-CSF and plerixafor. *Blood* 2010.
188. Battiwalla M, McIver Z, Haggerty J, Koklanaris E, Chawla K, Superata J, Childs R, Kurlander R, Stroncek DF, Khuu HM, Citrin D, Sabatino M, Leitman SF, Barrett J. T-lymphocyte depleted myeloablative HLA-matched sibling transplants; a platform for adoptive immunotherapy. *Blood* 2010.
189. McIver Z, Mielke S, Shenoy A, Fellowes V, Hahn K, Stroncek DF, Leitman SF, Childs R, Battiwalla M, Koklanaris E, Haggerty J, Savani BN, Rezvani K, Barrett AJ. Selectively T cell depleted allografts from HLA-matched sibling donors followed by low-dose post transplant

immunosuppression to limit disease relapse in patients with hematological malignancies. *Blood* 2010.

190. Fowler DH, Mossoba ME, Hakim FT, Kurlander R, Gea-Banacloche J, Sportes C, Hardy NM, Pavletic SZ, Steinberg SM, Khuu HM, Sabatino M, Stroncek DF, Leitman SF, Rowley SD, Donato M, Goy A, Friedman TM, Korngold R, Pecora AL, Levine BL, June CH, Gress RE, Bishop MR. T-Rapa cells safely accelerate alloengraftment after low-intensity chemotherapy. *Blood* 2010.
191. Pope M L, Sigmon JM, Trenbeath JL, Yau YY, Byrne KM, Leitman SF. Experience with donor reentry testing for hepatitis B core antibody. *Transfusion* 2011
192. Kelley WE, O'Donghaile D, Diggs K, Fowler D, Lozier J, Leitman SF. Heparin induced thrombocytopenia and thrombosis (HITT) in a peripheral blood stem cell (PBSC) donor. *Transfusion* 2011
193. O'Donghaile D, Kelley WE, Diggs K, Vasu S, Childs R, Barrett AJ, Leitman SF. Tandem granulocyte and peripheral blood stem cell (PBSC) collection. *Transfusion* 2011
194. Donahue RE, Tuschong L, Bauer TR, Hickstein DD, Yau YY, Leitman SF. Leukocyte integrin activation and alterations in parathyroid hormone levels following G-CSF administration. *Blood* 2011
195. Shah NN, Loeb D, Khuu H, Stroncek D, Raffeld M, Delbrook C, Richards K, Baird K, Levine J, Leitman SF, Mackall CL, Fry TJ, Wayne AS. A pilot trial of WT1 peptide-loaded allogeneic dendritic cell vaccine and donor lymphocyte infusion for WT1-expressing hematologic malignancies and post-transplant relapse. *Blood* 2011
196. Battiwalla M, McIver Z, Klotz J, Draper D, Haggerty J, Chawla K, Superata J, Stroncek D, Khuu H, Citrin D, Sabatino M, Leitman SF, Barrett AJ. Outcome after CD34+ selection with or without the addition of photo-allodepleted T lymphocytes in myeloablative HLA-matched sibling transplantation. *Blood* 2011.
197. O'Donghaile D, Yau YY, Pogue S, Kelley WE, Bolan CD, Leitman SF. Predictors of peripheral blood progenitor cell mobilization in an unrelated-donor population. *Transfusion* 2012.
198. Beaulieu GP, Ward DC, Lee-Stroka AH, Leitman SF, Flegel WA. Near fatal immune hemolysis following a minor ABO mismatched peripheral blood stem cell transplant. *Transfusion* 2012.
199. Bat T, Leitman SF, Calvo K, Chauvet D, Dunbar C. Measurement of the absolute immature platelet number reflects marrow production and is not impacted by platelet transfusion. *Blood* 2012.
200. Hasni SA, Illei GG, Nikolov NP, Hakim F, Grammer AC, Leitman S, Balow J, Austin H, Gea-Banacloche J, Oh U, Muraro P, Sportes C, Lipsky P, Gress R, Pavletic S. Lymphoablation including B cell depletion and autologous hematopoietic stem cell transplantation leads to long remissions in treatment-resistant systemic lupus patients. *Am Coll Rheumatol* 2013.

201. Panch S, Yau YY, Sweigart T, Diggs K, Leitman SF. Initial serum ferritin predicts number of therapeutic phlebotomies to iron depletion in secondary iron overload. *Transfusion* 2013.
202. Panch S, Yau YY, Kang E, Malech H, Leitman SF. Hematopoietic Progenitor cell mobilization in patients with chronic granulomatous disease and severe combined immunodeficiency. *Transfusion* 2013.
203. Wang X, Mendelsohn L, Rogers H, Leitman SF, Tallack M, Perkins A, Taylor JG, Noguchi CT, Kato GJ. Placenta growth factor 1s regulated by heme-bound iron via erythroid Krüppel-like factor in erythroid cells and 1s linked to iron status in vivo in sickle cell disease and hereditary hemochromatosis. *Blood* 2013.
204. Tageja N, Korde N, Yuan C, Cole K, Hsu J, Phang S, Avila D, Taylor T, Mulquin M, Zuchlinski D, Khuu H, Stetler-Stevenson M, Leitman SF, Landgren O, Sportes C. Carfilzomib and Bortezomib containing regimens yield high rates of MRD negative autologous hematopoietic progenitor cell grafts in plasma cell myeloma. *Blood* 2013.
205. Leitman SF, Tageja N, Korde N, Yau YY, Phang S, Hsu J, Cole K, Khuu H, Landgren O, Sportes C. Utility of an algorithm for use of plerixafor in filgrastim-based hematopoietic progenitor cell mobilization in patients with plasma cell myeloma treated with carfilzomib-lenalidomide-dexamethasone. *Blood* 2013.
206. Panch S, Yau YY, Kang E, Malech HI, Leitman SF. Hematopoietic progenitor cell mobilization in response to G-CSF is more robust in healthy African American compared to caucasian donors. *Blood* 2013.
207. Kadri S, Remy KE, Strich J, Gea-Banacloche J, Leitman SF. Dexamethasone/G-CSF-stimulated donor granulocyte transfusions increase resolution of invasive *Fusarium* infection in immunocompromised hosts. *Am Thor Society Meetings, San Diego. 2014 May 15-22.*
208. Purev E, Tian X, Pantin J, Reger RN, Cook L, Ramos C, Cho E, Purvey S, Prince P, Khuu H, Stroncek D, Leitman S, Townsley D, Young NS, Aue G, Childs RW. Excellent engraftment and reduced acute and chronic GVHD in ATG-refractory severe aplastic anemia following transplantation of a PBSC allograft containing CD34+ selected cells combined with non-mobilized donor T-cells. *Blood* 2014.
209. Purvey S, Purev E, Tian X, Cook L, Ramos C, Cho E, Prince P, Leitman S, Khuu H, Stroncek D, Reger R, Aue G, Childs R. High incidence of late, sustained and clinically inconsequential Epstein Barr Virus reactivation following combined unrelated cord blood and haploidentical CD34+ cell transplantation. *Blood* 2014.
210. Donahue RE, Metzger ME, Bonifacino AC, Parker DM, Leitman SF, Cullis H, Lienesch M. Optimization of the Spectra Optia for leukapheresis of very small subjects. *Blood* 2014.
211. Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Switzer GE, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Hays A, Kobusingye H, Besser RM, Miller JP, Drexler RJ, King R, Horowitz MM, Navarro WH, Confer DL. Donor age, baseline symptoms, and female gender are correlated with higher levels of peri-collection pain and symptoms and persistent discomfort one year after related donor BM and PBSC donation: an analysis of the Related Donor Safety Study (RDSafe). *Blood* 2014.

212. Donahue RE, Metzger ME, Leitman SF, Cullis H. Caloric loss associated with apheresis. Blood 2016 Dec. 2310a.